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ABSTRACT 
Bioprospecting is the examination of biological resources for features that 
may be of value for commercial development. It has the potential to create a wide 
range of benefits. New Zealand's rich biodiversity, especially its marine 
environment and indigenous knowledge makes it a prime target for bioprospecting 
activity. In response to New Zealand's obligations to implement access and benefit 
sharing regimes, to avoid the exploitation of its indigenous resources and loss of any 
potential benefits, New Zealand has begun developing a bioprospecting policy. 
However, New Zealand's development of a bioprospecting policy may have come 
too late to prevent the loss of potential benefits, at least in the near future. There are 
already a number of examples of products that have been developed using New 
Zealand's biological resources and traditional knowledge for which the benefits have 
not been shared with the owners of those resources. It is also unlikely that New 
Zealand would have either the legal avenues and or the financial resources to 
enforce its sovereign rights to its genetic resources retrospectively. If New Zealand 
wishes to secure benefits from bioprospecting it must therefore do so soon. 
This paper examines the issues surrounding bioprospecting, including the 
ownership and access of biological resources, protection of traditional knowledge, 
distribution of benefits, and intellectual property rights. It argues that to take 
advantage of the small window of opportunity New Zealand must review its existing 
legislation and make the changes necessary to facilitate any bioprospecting activity. 
Implementing specific legislation at this time could usurp the Wai 262 claim and 
unnecessarily restrict any bioprospecting activity reducing the benefits to New 
Zealand. 
The text of this paper ( excluding abstract, table of contents, footnotes, bibliography 
and appendices) comprises approximately 14589 words. 
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I INTRODUCTION 
In the aftermath of the International adoption of the Convention on 
Biological Diversity, many countries are moving to seek economic returns from the 
commercial use of their biological resources. Biodiversity prospecting or 
bioprospecting is "the examination of biological resources for features that may be 
of value for commercial development."1 The growing consumer demand for 
naturally sourced products, combined with technological advances m the 
pharmaceutical, agricultural and biotechnology industries have fuelled 
bioprospecting activities worldwide. 2 
Biotechnology is a multibillion dollar global industry, and bioprospecting is 
of growing interest to New Zealand's science agencies and large multinational 
companies, particularly given the extensive range of biodiversity, the untapped 
potential of our marine environment and technological advances in screening for 
bioactive substances. However, "whilst some of our species are endemic, their 
bioactive components may be found in other parts of the world or can be synthesised 
in a laboratory."3 In terms of benefiting from bioprospecting activities it is 
anticipated there is a window of opportunity where New Zealand has a comparative 
advantage over other countries, particularly developing countries.4 There is a 
concern that foreign researchers are currently benefiting from easy access to 
biological resources without sufficient capture of down stream benefits by New 
Zealand. 
There is currently no legal or policy framework for managing bioprospecting 
in New Zealand. Instead its regulatory framework is ad hoe, fragmented and reliant 
on legislation designed for other purposes. The framework is also not suited to 
maximising potential benefits or managing potential risks from bioprospecting 
activities. This enhances the risk of biopiracy, resulting in lost opportunities for 
1 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 3. 
2 S Laird and ten K Kate Biodiversity Prospecting: The Commercial Use of Genetic Resources and 
Best Practice in Benefit-Sharing (Earthscan Publications Limited, London, UK, 2002) 3. 
3 Ministry of Economic Development, above, 3. 
4 Ministry of Economic Development, above, 3. 
5 
managed access to biological resources in New Zealand. New Zealand
 is in the 
initial stages of developing a bioprospecting policy to address the risks 
associated 
with New Zealand's current policy regime. 
In order to examme bioprospecting in New Zealand the first part of th
is 
paper will set out the definition of bioprospecting, the international contex
t and then 
examine the existing statutory framework identifying what the potential im
plications 
the current framework has on bioprospecting. It will then discuss particu
lar issues 
for Maori, particularly the Wai 262 claim and the treatment of t
raditional 
knowledge. The second part of this paper will then examine the distrib
ution and 
sharing of the benefits. Finally, this paper presents a series of options that 
have been 
used by different countries and organisations to implement access an
d benefit 
sharing arrangements and proposes that a less restrictive approach should b
e taken to 
ensure that New Zealand can capture the benefits from the bioprospectin
g activity. 
and the distribution and sharing of those benefits. 
II WHAT IS BIOPROSPECTING 
A Definition 
Biodiversity prospecting or bioprospecting is "the examination of biologic
al 
resources for features that may be of value for commercial developme
nt."5 The 
features may include "chemical compounds, genes and their products or
, in some 
cases, the physical properties of the material in question."
6 This definition "only 
includes the search for products, which may be of potential comme
rcial use, 
excluding non-commercial biodiversity research, for example studies con
ducted by 
universities and independent research institutions."
7 
The term biological resources, has been defined in the Convention 
on 
Biological Diversity (CBD) to include "genetic resources, organisms
 or parts 
thereof, populations, or any other biotic component of ecosystems with 
actual or 
5 Ministry of Economic Development, above, 3. 
6 Ministry of Economic Development, above, 6. 
6 
potential use or value for humanity."8 This includes plants, animals, fungi , 
microorganisms and viruses, the parts and products thereof, which may be of value 
to humans.9 Biological resources are generally used in two ways, either for their 
physical components to directly make a product, or for the information those 
organisms contain. '0 
Bioprospecting is distinguished from other biotechnology research because it 
incorporates the concept of prospecting, which is the "search of biological material 
for as-yet-undiscovered substances and applications."' 1 It is also important to note 
that the definition of biological resources does not include human or human 
tissues. 12 Bioprospecting is not about genetic modification or issues associated with 
the collection and use of human tissue and genetic material. 13 Some of these issues 
will be considered by the review of the Human Tissues Act currently undertaken by 
the Ministry of Health. 
B The Nature of Bioprospecting 
The use of natural resources in the development of new products is an old 
phenomenon, dating back as far as 2600BC in Mesopotarnia. 14 Oils were used from 
cedar and cypress, liquorice, myrrh and poppy juice, among other things. These 
substances are still in use today for the treatment of a variety of illnesses and 
infections. Ancient Egyptian, Chinese and Indian documents also show that 
7 Ministry of Economic Development, above, 2. 
8 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 2. 
9 Kristy Hall Bioprospecting Position Paper: What is Bioprospecting and What are our International 
Commitments? (Ministry of Economic Development, 2003). 
'
0 John R Adair" The Bioprospecting Question: Should the United States Charge Biotechnology 
Companies for the Commercial Use of Public Wild Genetic Resources?" (l 997) 24 Ecology L.Q. 
131, 137. 
11 Antarctica ew Zealand Bioprospecting in Antarctica: Discussion Paper (Wellington, 2002). 
12 Refer Decision 11/11(2) of the Second Conference of the Parties of the Con ention on Biological 
Diversity. 
13 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 4. 
14 General Introduction 1.1 Plant-Derived Drugs atural products 
http ://wwwscholar.lib.vt.edu/theses/available/etd-72198-18137 / Wlfestricted/Body.pdf (last accessed 
7 August 2003). 
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medicine m these societies included numerous plant-based remedies and 
· 15 preventives. 
The growing consumer demand for naturally sourced products, combined 
with technological advances in the pharmaceutical, agricultural and biotechnology 
industries have fuelled bioprospecting activities worldwide. 
16 Nearly half of the 
world's 25 top selling drugs are derived from natural resources, and the global 
market value of pharmaceuticals derived from wealth from biological resources is 
estimated at $75-$150 billion (US).
17 Bioprospecting has been responsible for such 
discoveries as Quinine, the anti-malarial drug, from the bark of a Cinchona species, 
and anti-bacterial agents from the Penicillin species. 
18 Discoveries from 
bioprospecting have been utilised in other markets such as fragrances and flavours, 
horticulture, crop protection, botanical medicinal and cosmetics.
19 
C Where Is Bioprospecting Conducted? 
An essential aspect of bioprospecting is that it is a search for novel sources 
of organisms. This makes most micro-organisms, many marine environments, and 
extreme ecosystems such as that of the Antarctic the most sought after locations.
20 
The developing countries have been a primary target for bioprospecting because of 
their unique biodiversity and relatively untouched lands. New Zealand is also a 
potential hot spot for bioprospectors because of its isolation, its indigenous flora and 
fauna has developed in a particular way. New Zealand's Exclusive Economic Zone 
(EEZ) is the fourth largest in the world, which provides a rich source of marine 
material.
21 For exan1ple, the large number of hydrothermic vents in New Zealand's 
EEZ offers an opportunity to study micro-organisms that have developed in extreme 
15 Biodiversity, Biotechnology, and Law: West Africa 
<http ://www.aaas.org/international/africa/gbdi/mod2a.htm> (last accessed 7 August 2003). 
16 S Laird and ten K Kate Biodiversity Prospecting: The Commercial Use of Genetic Resources and
 
Best Practice in Benefit-Sharing (Earthscan Publications Limited, London, UK) 3. 
17 S Laird and ten K Kate, above, 3. 
18 Biodiversity, Biotechnology, and Law: West Africa 
<http://www.aaas.org/international/africa/gbdi/mod2a.htm> (last accessed 7 August 2003). 
19 S Laird and ten K Kate, above, 3. 
20 The Magic Pudding Company Pty Ltd Biotechnology Collaboration between New Zealand and 
Queensland: Opportunities for Growth (Report prepared for Industry New Zealand, 2003). 
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environments.22 There is also a wealth of indigenous knowledge that makes New 
Zealand an attractive place to bioprospect. 
There is evidence to suggest that bioprospecting is already being conducted 
m New Zealand by a "wide range of agencies, including domestic and foreign 
bioteclmology firms, universities and research institutions".23 An example of product 
development include Living Nature, a New Zealand based company using plants and 
clays to make cosmetic products. Their products are exported to Germany and the 
United States.24 Foreign biotechnology companies have substantial involvement in 
New Zealand's bioprospecting, although usually in collaboration with Crown 
Research Institutions (CRis). 25 However, it is difficult know exactly to what extent 
its resources are being targeted as there has been no formal research conducted into 
the scale of the industry. 26 
D Benefits of Bioprospecting 
Bioprospecting is an activity that has the potential to provide a variety of 
benefits for countries such as New Zealand. The benefits can be either monetary or 
non-monetary. The most commonly thought of financial benefit are the royalties 
from the end product, which are secured through the retention of intellectual 
property. However, they are not a guaranteed benefit, as only a small proportion of 
bioactive substances will ever make it to the stage of commercial production. Even if 
a product is developed there may be a number of inputs included in the final product, 
which makes it difficult to identify how one particular substance has contributed to 
the final product. 27 
21 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 4. 
22 Daniel Brown Bioprospecting: Problem Definition (Ministry of Economic Development Research 
Paper, 2001 ). 
23 Ministry of Economic Development, above, 3. 
24 Ministry of Economic Development, above, 3. 
25 Ministry of Economic Development, above, 3. 
26 Ministry of Economic Development, above, 3. 
27 Ministry of Economic Development, above, 7. 
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Bioprospecting is high cost and a high-risk process, with no guarantee of any 
financial returns at all. For example, even in the first six years of the bilateral 
bioprospecting contract between Costa Rica's National Institute of Biodiversity 
(INBio) and a United States phannaceutical company, Merck, no royalty payments 
were received from bioprospecting. 
As well as royalties, other financial benefits include bioprospecting fees, 
percentage or research budget, development of alternative income generating 
schemes and collection of samples, supply of biological material.
28 
Non-monetary 
benefits include acknowledgement in publication, joint research and increased 
scientific capacity, participation in planning and decision-making, control over 
san1ples and research, technology transfer, training in bioprospecting methods, 
collection and preparation of samples.
29 
There are a number of stages in a bioprospecting activity. The first stage 
includes the initial discovery of the material, screening for useful properties and 
describing new chemical structures. The second stage requires protecting the new 
chemical structures, usually by patenting. Patenting is the most relevant property 
right, as it enables the owner to have an exclusive right to control the commercial 
exploitation of an invention for a limited time.30 The next three stages include the 
product development, manufacturing and finally, if successful, the marketing of the 
final product. 31 
New Zealand is most likely to capture benefits in the early stages of the 
bioprospecting activity, as this is when the initial discovery of the material is made 
and screened for useful properties. 32 Benefits can be obtained from adding value to a 
discovery through the chain of scientific research and development, downstream 
28 Department for Environment and Heritage Access to Biological Resources in South Australia: 
Discussion Paper (South Australia, 2000). 
29 Columbia University School oflntemational and Public Affairs, "Access to Genetic Resources: An 
Evaluation of the Development and Implementation of Recent regulation and Access Agreements" 
(Environmental Policy Studies, Working Paper o 4, ew York, 1999) 75. 
30 Other intellectual property rights include trademarks, copyrights, plant variety rights and designs. 
31 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002). 
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industrial development related to scientific discoveries, royalty streams to the 
"owner" of a bioactive discovery that is commercially developed, increased capacity 
of New Zealand 's scientific sector through bioprospecting research and increased 
scientific knowledge of New Zealand's biology and ecology. 33 
However, there may only be a narrow window of opportunity for New 
Zealand to capture and maximise possible economic benefits from access to its 
biological resources. Australian policy work on bioprospecting has suggested there 
is a 5-7 year window of opportunity available. 34 This is because as technology 
advances, the approach to the development of new drugs will increasingly shift from 
the screening of natural products to rational drug design. There will be the ability to 
synthesise micro-organisms in a laboratory without prior knowledge of their 
existence in nature. The new screening technologies also seem to reduce the value of 
local knowledge for increasing the 'hit' rate in the screening of biological materials. 
It is also likely that discoveries can be made elsewhere, although there are some 
species endemic to New Zealand, the substances derived from bioprospecting could 
be found in other species, in other parts of the world. If this is the case, legislative 
responses may be too slow to capture the opportunities available. 35 
E Intellectual Property 
Intellectual property creates property rights over intangible information, 
including industrial designs, inventions and images. The underlying rationale for 
intellectual property right systems is that they offer protection to new innovations 
and therefore create incentives for further investment in developing future 
innovations. In the context of genetic resources, intellectual property rights are often 
defined and protected in the form of patents. 36 Patenting is the most relevant 
property right, as it enables the owner to have an exclusive right to control the 
32 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 7. 
33 Ministry of Economic Development, above, 7. 
34 Ministry of Economic Development, above, 7. 
35 Ministry of Economic Development, above, 7. 
36 The Patents Act 1953. 
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commercial exploitation of an invention for a limited time.
37 
Patents will not be 
granted for micro-organisms found in their natural state, only if they have been 
modified.38 A patent will also only give the applicant protection for twenty years, 
once that time period is over the knowledge is part of the public domain. The 
Government is currently reviewing the Patents Act and whether the boundaries of 
patentability should be extended.
39 
III INTERNATIONAL COMMITMENTS 
There are a number of international commitments of direct relevance to the 
management of bioprospecting activities. Many of these commitments are binding 
whereby Parties have a legal obligation to adhere to the requirements of these 
documents. Examples include the Convention on Biological Diversity (CBD), the 
Trade Related Intellectual Property Services Agreement (TRIPS), and the United 
Nations Convention on the Law of the Sea (UNCLOS). Others are non-binding 
moral commitments including Agenda 21, the Rio Principles, and the Millennium 
Development Goals. These are important commitments to take into account when 
implementing any policy related to bioprospecting. However, apart from a 
discussion on the CBD and a brief overview of the TRIPS agreement, considerations 
of these other international commitments are outside the scope of this paper. 
A The 1992 Convention on Biological Diversity 
The Convention of Biological Diversity (CBD), Rio de Janeiro, 5 June 1992, 
represents the first international commitment to the preservation of biological 
diversity on a global scale and has been ratified by more than 180 countries, 
including New Zealand.40 Although the Convention does not specifically refer to the 
activity of bioprospecting it does cover a number of closely related issues involved 
37 Kim Connolly-Stone Patents, Property Rights and Benefit Sharing Issues in Relation to 
Bioprospecting Bioprospecting in Antarctica Workshop 7-8 April 2003 . Other intellectual property 
rights include trademarks, copyrights, plant variety rights and designs. 
38 Kim Connolly-Stone, above, 2003. 
39 See www.iponz.govt.nz. 
40 ew Zealand ratified on 16 September 1993 . 
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in the bioprospecting process. This is evident in the Convention's three objectives: 
conserving biological diversity, using natural resources sustainably, and fairly and 
equitably sharing benefits derived from the use of genetic resources. 41 The last 
objective is of particular importance to developing countries, which hold most of the 
world's biodiversity, but consider that they do not receive a fair share of the benefits 
from the use of their resources in products resulting from bioprospecting.42 
Indigenous peoples, including Maori, share similar concerns. 
The Convention recognises "the sovereign rights of a nation to exploit their 
own biological and genetic resources according to their environmental policies, 
provided they do so in accordance with the Charter of the United Nations and the 
principles of international law." 43 States also have the responsibility to ensure that 
activities within their jurisdiction or control do not cause damage to the environment 
of other States or areas beyond the limits ofnationaljurisdiction.44 
Article 15 of the CBD 45 "recognises the sovereign rights of States over their 
natural resources,"46 including the authority to determine access and benefit sharing 
regimes in line with the Convention.47 This is one of the most significant objectives 
as it establishes that nations have sovereign rights over their genetic resource, and 
that the source country can expect some form of compensation for their use. 48 This 
reverses the principle of "common heritage of mankind" which held that the genetic 
resources of the world had belonged to everyone.49 This Article also specifies the 
parameters for access to genetic resources which are that the source country should 
provide access to genetic resources subject to "prior informed consent" (PIC) unless 
41 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 1. 
42 Secretariat of the Convention on Biological Diversity, Bonn Guidelines on Access to Genetic 
Resources and Fair and Equitable Sharing of the Benefits Arising out of their utilisation, 2002, iii. 
43 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 3. 
44 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 3. 
45 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 15 . 
46 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 15(a). 
47 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 15(2). 
48 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 15 , para I. 
49 Roger A Sedjo "Property Rights, Genetic Resources, and Biotechnological Change" ( 1992) 35 J.L 
& Econ 199, 206. 
13 
that Party decides pnor informed consent 1s unnecessary
50 
and where granted it 
should be on "mutually agreed terms"
51 
PIC is one of the mam responsibilities of the governments when 
implementing their obligations regarding access to genetic resources. PIC ensures 
that governments can evaluate bioprospecting activity before it occurs and therefore 
are able to control access over the raw biological materials. This doctrine can extend 
to any group, indigenous or otherwise provided that they have some recognisable 
interest in the genetic resource. 
52 
Articles 15 to 19 contains obligations that relate more closely to 
bioprospecting, they request that contracting parties adopt measures that aim to 
achieve the fair and equitable sharing of benefits arising from the commercial (and 
other) utilisation of genetic resources, and the results of research and development, 
with the State that provided the resource. 53 "Genetic resources" are defined as "any 
material of plant, animal, microbial or other origin containing functional units of 
heredity ... of actual or potential value."54 However, sections 15 to 19 specify that 
"only those that are provided by Contracting Parties that are countries of origin of 
such resources or by the Parties that have acquired the genetic resources in 
accordance with this Convention."55 This suggests that any access and benefit 
sharing regimes developed under the CBD only apply to native or endemic species. 
Such regimes would only cover introduced species, biochemicals or other biological 
products or cell components not containing DNA or RNA, if they were acquired 
under the provisions of the Convention.
56 
5° Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 15(5). 
5 1 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 15(4). 
52 Convention on Biological Diversity Building A New Partnership: Draft Guidelines on Access and 
Benefit Sharing Regarding the Utilisation of Genetic Resources (Switzerland Submission, 
UNEP/CBD/WG-ABS/ l/INF/5). 
53 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 15(7) . See also Articles 16 
and 19 regarding access to and transfer of technology, and handling of biotechnology and distribution 
of its benefits. 
54 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 2. 
55 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 15(3). 
56 Kristy Hall Bioprospecting Position Paper: What is Bioprospecting And What Are Our 
international Commitments? (Ministry of Economic Development, 2003) . 
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The Convention text is very general and does not specify the method for 
achieving improved access and benefit sharing. However, a number of Articles 
request for the transfer of technology between Parties,57 information exchange,58 
scientific cooperation,59 and the provision of funding. 60 The Conference of the 
Parties (COP), for the CBD have produced a set of policy guidelines called the Bonn 
Guidelines on Access to Genetic Resources and Fair and Equitable Sharing of the 
Benefits Arising Out of their Utilisation. These are non-binding guidelines which 
establish a number of "roles and responsibilities"61 for contracting parties. Guidance 
is provided on matters such as the negotiation, monitoring and evaluation, 
implementation and enforcement of access benefit sharing (ABS) agreements 
(contracts), procedures for obtaining prior informed consent62 and mechanisms for 
benefit sharing. 63 The World Intellectual Property Office provides technical advice 
to the CBD on ABS implementation issues. 
The Convention also recognises the association between indigenous people, 
traditional knowledge and biological resources, including the need to ensure that the 
use of such knowledge is done with the approval and acknowledgement of the 
holders of that knowledge and that equitable benefit sharing with indigenous 
knowledge holders occurs. 64 The CBD has established an ad hoe Working Group to 
help interpret and implement Article 8U). 65 
B TRIPS 
The Agreement on Trade Related Aspects of Intellectual Property (TRIPS) 
1s the most relevant agreement for bioprospecting under the World Trade 
Organisation (WTO). It was "developed in order to reduce distortions and 
impediments to international trade, and taking into account the need to promote 
57 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, arts 1 and 16. 
58 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 17. 
59 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 18. 
6° Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, arts 1 and 20. 
61 Bonn Guidelines Section II. 
62 Bonn Guidelines Articles 24 to 40. 
63 Bonn Guidelines Article 23 . 
64 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 8U) . 
65 COP Decision IV/9. 
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effective and adequate protection of intellectual property rights, and to ensure that 
measures and procedures to enforce intellectual property rights do not in themselves 
become barriers to legitimate trade."66 The Agreement sets out the mm1mum 
intellectual property rights standards for all WTO members. These standards, 
especially patents have an impact on biodiversity management. In the case of 
patents, "it provides generally that patents must be available for inventions, whether 
products or processes, in all fields of technology. "
67 
C TRIPS and CBD 
There is a concern that the TRIPS agreement is incompatible with the 
objectives of the CBD and therefore the two agreements cannot be implemented 
consistently. This is based on the conflicts between the goals of these two 
Conventions. The TRIPS agreement allows private rights to be established over 
inventions based on genetic resources through patents and the CBD recogmses 
sovereign rights over their genetic resources. 
Those that purport this view (primarily developing countries), propose 
amending Article 27(3)(b) of the TRIPS Agreement to make the grant of patents 
contingent on the provision of a declaration of the origin of genetic resources, proof 
of prior informed consent where the genetic resources are the subject of traditional 
knowledge and evidence of fair and equitable benefit-sharing ensuring compliance 
with CBD provisions.68 This view also addressed the difficulties that States may 
encounter when implementing the amendment to Article 27(3)(b ), for example 
implementing domestic legislation that can cope with identifying the origin of 
species. 
The opposing view is that there is no conflict between the two agreements. 
The fact that the TRIPS agreement is silent on biodiversity issues does not 
necessarily mean it is in conflict with the CBD. Rather it preserves the flexibility of 
66 WTO Ministerial Declaration, September 1986; TRIPs, Preamble. 
67 Sarma Lakshmi "Biopiracy: Twentieth Century Imperialism in the Form oflntemational 
Agreements" (1999) 13 Temp.Int ' l & Comp.L.J. 107,124. 
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individual members to design and implement domestic intellectual property systems 
that meet obligations under the TRIPS Agreement and national priorities under the 
CBD. 
At the international level, work is being carried out by WIPO to look at ways 
of doing this and in New Zealand, for example, the new Trade Marks Bill is 
expected to contain provisions to ensure that inappropriate registration decisions are 
not made in respect to the registration of Maori words and symbols. Other options, 
such as a special sui generis ( or stand alone) system of protection for indigenous 
intellectual property are also being examined. 69 
On a related front, the WTO is currently rev1ewmg the choice Members 
presently have over whether to allow the patenting of plants, animals (including 
humans) and essentially biological processes for the production of plants or animals. 
In New Zealand, Maori have traditionally opposed the patenting of life forms for 
spiritual and cultural reasons. 
IV NEW ZEALAND AND BIOPROSPECTING 
A New Zealand Biodiversity Strategy 
New Zealand's domestic obligations to facilitate access to and benefit-
sharing arising from the use of its biological resources are based on the New Zealand 
Biodiversity Strategy. This strategy seeks to implement New Zealand's international 
obligations under the CBD. 70 
Objective 4.3 of the biodiversity strategy is to "Develop an integrated policy 
and legislative framework for managing bioprospecting in New Zealand, including 
arrangements for sharing benefits from the use of genetic resources, which are 
consistent with international commitments". This strategy also creates obligations 
68 Ministry of Foreign Affairs and Trade The WTO Agreement on Trade Related Aspects of 
Intellectual Property Rights (TRIPS) (Information Paper, 1999). 
69 Ministry of Foreign Affairs and Trade The WTO Agreement on Trade Related Aspects of 
lntellectual Property Rights (TRJPS) (Information Paper, 1999). 
70 The New Zealand Biodiversity Strategy, Febmary 2000 
<http://www.doc.govt.nz/Conservation/The-New-Zealand-Biodiversity-Strategy/index.asp> (last 
accessed 7 July 2003). 
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for the protection of Maori traditional knowledge in relation to biological resources, 
and the sharing of benefits derived from this knowledge.
71 
B Oceans Policy 
An improved access regime for bioprospecting in the marine environment 
also compliments work being done under the current ocean policy review. For 
example, the oceans policy is identifying the means by which marine activities can 
contribute to the wealth and wellbeing of New Zealanders. Bioprospecting has the 
potential to lead to valuable discoveries and up skill our scientific sector. The 
proposed Oceans Policy will provide overarching direction for decision making on 
all activities in the oceans. This work will seek to improve the access regime for 
bioprospecting in the marine environment.
72 
C Current New Zealand Policy 
New Zealand is currently in its early stages of developing a policy on 
bioprospecting. The Ministry of Economic Development took the lead role on the 
project on 18 May 2001. Prior to this, Department of Conservation (DoC) led work 
in the area, as part of the Central Government Co-ordinating Group for Biodiversity, 
established to implement the New Zealand Biodiversity Strategy.
73 The release of 
the discussion document in November 2002 and the submissions received m 
response to the document has highlighted the respective issues in relation to 
bioprospecting for New Zealand. This section of the paper will identify the current 
issues of concern for bioprospecting in ew Zealand. 
D Existing Statutory Framework 
J Ownership of resources 
7 1 The ew Zealand Biodiversity Strategy, February 2000 
<http://www.doc.govt.nz/Conservationffhe-New-Zealand-Biodiversity-Strategy/index.asp> (last 
accessed 7 July 2003). 
72 Oceans Policy http ://www.oceans.govt.nz/policy/index.html (last accessed 25 June 2003). 
73 Daniel Brown Bioprospecting: Problem Definition (Ministry of Economic Development Research 
Paper, 200 I) . 
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The ownership of biological material is fragmented and there is no 
framework specific to bioprospecting in New Zealand. The Wildlife Act 1953 grants 
Crown ownership over all indigenous land mammals, most birds, reptiles and some 
invertebrates irrespective of where they are found. 74 The common law vests 
ownership, of microorganisms, specimens of plants and fauna (not covered by the 
Wildlife Act) with the relevant landowner (including private landowners). 75 
The Native Plants Protection Act 1934 prohibits the taking of 'significant' 
quantities of most native plants without landowner permission. On public land, that 
permission must come from government or local authorities. Exceptions are made 
for medicinal, research or horticultural plant uses and for certain plants, such as 
kanuka, manuka, bracken and nettles and related species, i.e., does not apply to 
mosses, lichens or algae. 76 The Continental Shelf Act 1964 vests all rights that are 
exercisable by New Zealand with respect to the continental shelf and its natural 
resources in the Crown. 77 
The Crown does not formally own fish and marine species other than marine 
mammals, but most are managed under the Fisheries Act.78 The Crown asserts 
management control over all marine mammals through the Marine Mammals 
Protection Act 1971. 
DoC manages access to the land it administers under the Conservation Act 
1987, and for granting others possession of indigenous plant and animal material 
from that land. This Act applies to the public conservation estate and includes both 
land and water out to the territorial sea (12NM). This includes about 30 per cent of 
New Zealand's landmass,79 over 1,000 threatened species, including the preservation 
of indigenous freshwater fisheries and the protection of recreational freshwater 
74 Wildlife Act 1953, section 3. 
75 However, it has been suggested that 'much indigenous biodiversity on private land is unprotected." 
Cited in F AO, New Zealand Country Report to the FA O International Technical Conference on Plant 
Genetic Resources: Leipzig (1996) 3 I. 
76 Wildlife Act 1953, section 4(2). 
77 The limits of New Zealand's continental shelf are currently being defined and must be submitted to 
the United Nations Commission on the Limits of the Continental Shelf in 2009. 
78 If they are part of a marine protected area they are managed under the appropriate legislation. 
79 See Conservation Act 1987. 
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fisheries and freshwater fish habitats. DoC is the authorised agency for the purposes 
of that taking of any marine life or material in any marine reserve.
80 
However, 
currently DoC cannot manage commercial activities in marine reserves as the 
Marine Reserves Bill is currently under review.
81 
2 Access to resources- private land 
On private land, the landowner is able to grant access to and possession of 
any biological material except for species covered by both the Wildlife Act 1953 and 
the ative Plants Protection Act 1934. 82 In this case the private landowner can 
grant access to the land, but access to the actual resource will require consent from 
the Crown manager. It is anticipated that biodiscovery as a process of bioprospecting 
will not involve the Resource Management Act 1991 (RMA). The Act is only likely 
to be triggered further downstream in the biotechnology continuum for processes 
such as bioharvesting. 83 
3 Access to resources - crown managed areas 
Access to biological resources on the Conservation Estate is provided for 
under Part 3B of the Conservation Act.84 The concession regime also applies to the 
Wildlife Act.85 A concession must be obtained to carry out any commercial
86 
or 
research activity in the conservation area. 87 DoC could carry out bioprospecting on 
80 Marine Reserves Act, section 11 b. 
81 Jane Gunn Bioprospecting in the Marine Environment (Ministry of Economic Development 
Research Paper, 2003). 
82 However, it has been suggested that "much indigenous biodiversity on private land is unprotected." 
Cited in F AO, New Zealand. Country Report to the FAO International Technical Conference on Plant 
Genetic Resources: Leipzig (1996) 31. 
83 Rebecca Macky Bioprospecting in New Zealand: Access to Resources- on land, in water bodies 
and in the coastal marine area (Ministry of Economic Development, 2003). 
84 Conservation Act 1987, section 170(2) states no activity should be carried out in a conservation 
area without a concession. There are some exceptions to this-including those taken without specific 
gain/reward for the activity. An activity includes a trade, business or occupation. 
85 A concessions regime applies in wildlife sanctuaries, wildlife refuges and, wildlife management 
reserves under section 14AA of the Conservation Act 1987. 
86 Conservation Act 1987, section Q 17. 
87 There are some exceptions to this, including those undertaken without specific gain/reward for the 
activity. 
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the public conservation estate without a concession88 or resource consent under the 
RMA. However, this is presumed to only apply for research purposes. 
The application process for these concessions or permits is outlined in the 
Permissions Standard Operating Procedure (SOP), which is a separate document 
from the legislation. The application process varies depending upon the potential 
effects of the activity. A DoC concession only gives approval for the one collection 
activity and may be granted subject to conditions of consent. Applications can be 
either high or low impact depending on their impact. Low impact (non notified 
applications) can take 2 days, high impact (notified) 4-6 weeks. The timelines are 
enlarged if there is a commercial component. The main difference is that non-
notified concessions will take approximately six weeks to approve and notified 
concessions will take approximately six months for approval. DoC administers and 
manages conservation areas, natural and historical reserves through conservation 
management strategies (CMS), conservation management plans (CMP) and 
freshwater management plans (MP) under the Conservation Act. 89 An activity must 
be consistent with both a CMP and CMS in order to obtain a concession approvaI.90 
4 Marine environment 
Under the Fisheries Act 1996, initial access to a manne resource can be 
obtained by provision of a special permit issued by the Ministry of Fisheries (Mfish) 
that exists for the taking of any "aquatic life" for non-commercial, scientific or 
research purposes.91 The Fisheries Act has an extremely wide definition of aquatic 
life and fisheries resources, which encompass anything that might be taken for the 
purposes of bioprospecting. 92 This would include, for example, sponges, seaweed, 
fish species, marine organisms and fresh water algae. 93 
88 Conservation Act 1987, section 17 0( 1 )( d) states a concession is not required for an activity carried 
out by DoC in the exercise of its functions . 
89 The CMS and CMPs documents are provided for in Part 3A of the Act and are generally area 
specific describing why an area is important and they recommend how to manage change. 
9° Conservation Act 1987, section 17T. Where there is no CMP/CMS the Minister can grant a 
concession after consideration is given to sections 17S, 17T, 17U. (section l 7W(2)). 
91 Fisheries Act 1996, section 97. 
92 ote that minerals are managed under the Crown Minerals Act 1991 and not the Fisheries Act. 
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Special permits are granted at the discretion of the chief executive and 
usually limit access to the minimum amount of "fish" necessary for the research, 
which are usually san1ples of less than 30kg.94 Special permits are only granted for 
investigative research and they do not provide for on-going access rights or 
exclusive access. They are also not issued where quota or a fishing permit already 
exists because it would undermine existing access arrangements and property rights 
in that fish stock. 95 
The application process for a special pem1it is not set out in the Fisheries 
Act; instead the process is set out in the Special Permit Application Information 
Sheet, which has been prepared by Mfish. The process requires the applicant to 
complete an application form, provide a detailed research proposal, complete a client 
information sheet, and provide detailed information on the species, quantities 
required, vessel, method of extraction, personnel and it goes on. 
96 The decision 
process may also require an independent internal review or consultation with others 
who may be affected. The applications are individually assessed and costs are 
recovered according to a time-based fee. The applications may also take a year or 
more to process.97 
In practice most bioprospecting has been opportunistic and occurred while 
undertaking other marine scientific research. Consequently Mfish has usually issued 
umbrella research permits to New Zealand Crown Research Institutions (CRI's/
8
, 
which avoid the need for individual of separate research purposes of bioprospecting. 
However, Mfish could be excluding potential bioprospectors from obtaining permits 
because of their preference to issue special permits to existing players, like CRls. 
99 
93 Jane Gunn, above, 2003 . 
94 Jane Gunn, above, 2003 . 
95 Ministry of Fisheries Bioprospecting New Zealand (submission to Ministry of Economic 
Development, 2003). 
96 Jane Gunn , above, 2003). 
97 Jane Gunn, above, 2003). 
98 Mfish advise that generic investigative research special permits are ( or have been) held by NIWA, 
G S, IRL and the Museum of New Zealand and that these agencies can and do take samples in 
r:rtnership with overseas inte_rests. . . . . 
Jane Gunn B1oprospectmg 111 th e Manne Environment (M1mstry of Economic Development 
Research Paper, 2003). 
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5 Foreign vessel approval process 
The Ministry of Foreign Affairs and Trade is the responsible agency for 
consenting to and handling any applications for marine scientific research in the 
EEZ and on the continental shelf. 100 MFAT have recently reviewed procedures for 
assessing requests from foreign governments wishing to conduct marine scientific 
research in New Zealand's jurisdiction. As a result of the review, the Ministry is 
endeavouring to identify an appropriate agency to coordinate inter-departmental 
consultation on applications and a central clearinghouse for all data, reports, samples 
and other information received as a result of foreign research vessels' activities. 
6 Continental Shelf Act I 964 and the Territorial Sea, Contiguous Zone 
and EEZ Act I 977 
The Continental Shelf Act 1964 establishes a regime to manage the natural 
resources of the continental shelf. The Act regulates prospecting for minerals and 
petroleum, but not other natural resources although it does exert sovereign rights 
over sedentary living organisms. The Territorial Sea, Contiguous Zone and EEZ Act 
1977 provides for the exploration, exploitation, conservation and management of the 
resources in the zone. MF AT is the responsible agent for both these Acts. 101 
E Issues with Existing Access Regimes to Biological Resources 
I On crown-managed land 
There are a number of issues with the existing access regime for land, which 
has the potential to create barriers for bioprospecting in New Zealand. The objective 
of the Conservation Act is to provide protection and control over the public 
conservation estate. This potentially conflicts with bioprospecting activity, which is 
commercialising biological resources. The current concessions regime and 
100 This is in accordance with Article 246 of the United Nations Convention on the Law of the Sea 
(UN CLOS) which states that marine scientific research in the EEZ and on the continental shelf may 
only be conducted with the consent of the coastal state. 
101 Jane Gww, above, 2003. 
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conservation management strategies, and conservation plans do not adequately
 
provide for bioprospecting and the process is very complicated. One consequence o
f 
this is that the bioprospectors will prefer to go to private landowners because it wil
l 
be easier to obtain consent for any activity. 
2 In the marine environment 
The current statutory framework for managmg access and ownership in 
relation to bioprospecting in the marine environment has created a vast amount o
f 
uncertainty. The confusion has been compounded by the various agencies and thei
r 
different information requirements, decision-making criteria, procedures and
 
timeframes. In particular the special permit issued under the Fisheries Act is no
t 
particularly conducive to bioprospecting activity. The approval process i
s 
discretionary and as each application is determined on a case-by-case basis th
e 
outcomes cannot be predicted with sufficient certainty. The terms and conditions i
f 
imposed usually require release of information, which could be commercially
 
sensitive. The process is time consuming and the costs of the applications are
 
variable depending on the time it takes to process the application. '
02 The permits are 
limited to investigative research and would not be applicable where th
e 
bioprospector required on-going access or ownership of the aquatic resource. All o
f 
these issues could act as an impediment for bioprospectors as overall it just seems to
 
hard. 
3 For both land and marine resources 
There are difficulties with using the existing processes both in the terrestrial and 
marine environments for bioprospecting. In particular, the various managemen
t 
controls under the different pieces of legislation consist of ad hoe processes, are
 
expensive and time consuming. In addition, the management responsibilities of 
different agencies are often conflicting, for example between DoC and Mfish in
 
regard to freshwater resources. There is also ad hoe integration of related processe
s 
102 
Ministry of Fisheries Bioprospecting New Zealand (submission to Ministry of Econom
ic 
Development, 2003). 
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where duplicate consents are often required, for example foreign research vessels 
require permits from both MFAT and Mfish. 
There are difficulties in collecting statistical information on the extent of 
bioprospecting activity being undertaken. There is no central place where all the 
information is available for applicants about the required approval process for 
bioprospecting in marine environment. There is not even a single point of contact 
within agencies such as the Mfish, DoC and MF AT. Different officials provide 
different advice. This can be frustrating and confusing for applicants. 103 
There is no standard approach for dealing with intellectual property rights 
within the current regimes. A benefit sharing arrangement could potentially be a 
condition under the Conservation Act and the special permit under the Fisheries Act, 
however there is no current system to do so. Any future bioprospecting policy 
framework would need to recognise that property rights have been created under the 
quota management system. This includes testing for and developing the biological 
properties from any part of the species in question, including by-products and 
waste. 104 Therefore there would need to be a consultative mechanism implemented 
for all those who may have an interest in the resource. 
The current framework does not adequately address export controls or 
measures to track and secure benefits for New Zealand that may result from 
commercial discoveries and patenting of biological material. Only the Marine 
Mammal Protection Act 1978, the Customs Export Prohibition Order 2002 and the 
Plants Act 1970 have some export controls. However, these do not cover all 
indigenous organisms, especially those on private land or in the vast majority of the 
marine environment. The following is a summary of the current statutory framework 
and implications this may have for bioprospecting. 
103 Jane Gunn Bioprospecting in the Marine Environment (Ministry of Economic Development 
Research Paper, 2003). 
104 Ministry of Fisheries Bioprospecting New Zealand (submission to Ministry of Economic 
Development, 2003). 
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F Other Processes 
J The moratorium on the public conservation estate 
Since 1995 DoC have not exercised their delegated authority for issuing 
permits for the collection of indigenous genetic resources from the conservation 
estate whether commercial or non-commercial in nature. There has effectively been 
a moratorium on the public conservation estate, with the exception that collection of 
indigenous flora and fauna for authentic non-bioprospecting research or for 
education would be permissible. This was intended to safeguard the Government's 
options in response to the Wai 262 claim, by preventing the commercialisation of 
material that may later be subject to Waitangi Tribunal recommendations and 
"bi · 105 poss1 e government action. 
There is a question as to whether it is appropriate that DoC's statutory 
function powers can be suspended due to the existence of the Wai 262 claim. In 
1996 the Conservation Amendment Act put in place the current concessions regime, 
1 year after the moratorium was put in place. It would seem to be ultra vires to have 
a policy that nullifies the operation of the legislative provisions. Therefore all 
applications under this regime would have to be considered on a case-by-case basis 
through the statutory process and a decision would need to be made on the merits. 
106 
This is supported by section 30(l)(a) of the Conservation Act 1987. Section 4 of the 
Conservation Act also requires the decision-maker to give effect to the principles of 
the Treaty of Waitangi . Although this does depend on the nature of the application 
and who will be affected. Any concerns will be part of the overall considerations in 
relation to the application. 
It is still unclear as to whether the moratorium is still in place, as DoC has 
not formally addressed this issue. In a recent draft general policy on the 
Conservation Act and related legislation DoC have stated that "the Department will 
seek to avoid actions which would create a grievance or prevent the redress of 
105 Interview with Caron Mounsey-Smith, Senior Policy Analyst (the author, Wellington, 8 
September, 2003). 
106 See Conservation Act 1987, section 30(l)(a) . 
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Treaty claim" 107 which suggests that there still may be restrictions. However there is 
currently confusion in the research community and this acts as a disincentive for 
bioprospectors. 
2 Fisheries moratorium 
Since 1992 the Ministry of Fisheries has placed a moratorium on issuing new 
commercial fishing permits. The moratorium is in place due to the absence of 
sustainable management regimes systems and not to compromise the Treaty 
partner's rights in the allocation of fisheries resources. However, the Fisheries Act is 
currently being revised and it is proposed that this moratorium be lifted due to a 
revised framework for authorising commercial fishing. 108 
G Access to Biological Resources in Existing Databases and Collections 
There is a large amount of scientific information already collected on 
biodiversity that is scattered around various New Zealand databases. 109 Each 
database has its own management regime and access conditions. It is anticipated that 
information contained in some of these resources will increasingly be used as 
alternative sources to the natural environment and therefore represents an 
increasingly valuable resource. The Foundation for Research, Science & Technology 
(FORST) and the Ministry of Research Science and Technology (MORST) are 
currently undertaking a review of the twenty-five databases and collections 
designated nationally significant. The review will include considerations of access 
and benefit sharing provisions, however, the review is not intended to go beyond 
these twenty-five databases and collections and it will not explicitly include the 
exploration of policy options for the databases/collections managed by Crown 
agencies responsible for providing access to biological resources.' ' 0 
107 The Department of Conservation Draft General Policy Conservation Act and Related l egislation 
August 2003. 
108 Jane Gunn Bioprospecting in the Marine Environment (Ministry of Economic Development 
Research Paper, 2003). 
109 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 24. 
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H Treaty of Waitangi and Maori Interests 
The use of indigenous biological resources for commercial outcomes raises a 
number of issues for Maori. These are the ownership and protection of traditional 
knowledge (mataaranga Maori), ethical issues concerning the ownership of genetic 
resources, the patenting of life forms, the importance of consultation with iwi and 
the involvement of Maori in the decision-making process.
111 This section will 
consider two of the main areas of concern that potentially create uncertainty for 
bioprospecting in New Zealand. 
1 Wai 262 claim 
The ownership of indigenous biological resources is an issue, which is 
primarily contained within the context of the Wai 262 claim. Ngati Kuri, Ngati Wai, 
Te Rarawa, Ngati Porou, Ngati Kahungunu and Ngati Koata lodged this claim in the 
Waitangi Tribunal in 1991. It alleges that the Crown has breached its obligation to 
protect the cultural and intellectual property of Maori.
112 This claim arises from 
Article II of the Treaty of Waitangi, which guaranteed Maori "full chieftainship of 
all their possessions (taonga)." Taonga literally means "treasures" rendered in the 
English version of the Treaty as natural resources including lands, forest, fisheries 
and other properties. 
The claim asserts that the Treaty guarantees rights of ownership, control, and 
authority over the genetic resources of indigenous flora and fauna, and cultural and 
intellectual heritage and traditional knowledge. It also asserts that the Crown is in 
breach of Article II of the Treaty through the enactment of legislation, including the 
110 Ministry of Economic Development, above, 24. 
111 
Ministry of Economic Development: Overview of Major Issues raised by Stakeholder groups. 
http ://www.med.govt.nz/ers/nat-res/bioprospecting/submissions/summary/summary-02.html (last 
accessed 4 August 2003). 
11 2 Ministry of Economic Development< http://www.med.govt.nz/ers/nat-
res/bioprospecting/bioprospecting-qa .html> (last accessed 25 June 2003). 
28 
f 
1 
i 
1 
Patents Act, which is inconsistent with those rights. 113 Therefore the Wai 262 claim 
has implications on the management of biological resources. 
The claim entered the hearing stage in 1998 and since that time the Tribunal 
has finished hearing tangata whenua evidence, tangata whenua export witnesses and 
Tribunal commissioned researchers. As tangata whenua and some expert evidence 
have been presented and further Statements of Claim filed, the number and scope of 
the claim issues has increased. To date Wai 262 claim issues have not been 
rationalised either collectively by claimants across their Statements of Claim or by 
the Tribunal. 114 
On 28 July 2002, in response to a Tribunal direction, the Crown filed its 
Statement of Response, which responds to the statements of claim, filed by the 
claimants. By way of Memorandum of Directions dated 30 May 2002, the Waitangi 
Tribunal decided that all remaining Wai 262 hearings were to be put on hold 
pending the formulation by the Tribunal of a Statement of Issues for Wai 262 . Then 
all the parties involved will have the opportunity to comment and this will form the 
focus of the Tribunal's final report. The Tribunal has not yet released its Statement 
oflssues. 115 The Wai 262 inquiry is still some way from completion. 
Concerns similar to those in Wai 262 have also been expressed in the 1993 
Mataatua Declaration on the Cultural and Intellectual Property Rights of Indigenous 
Peoples held in Whakatane. 11 6 The Declaration, was formulated at the First 
International Conference of the Cultural and Intellectual Property Rights on 
Indigenous Peoples, calls for a "moratorium on any further commercialisation of 
indigenous medicinal plants ... must be declared until indigenous communities have 
11 3 M Roberts, W orman, N Mininnick, D Wihongi and C Kirwood Kaitiakitanga: Maori 
Perspectives on Conservation, Pacific Conservation Biology (Surrey Beatty and Sons, Sydney, 
Australia, 1995) 7-20. 
11 4 Ministry of Economic Development <http://www.med.govt.nz/buslt/ intprop/info-sheets/wai -
262.html> (last accessed 25 June 2003). 
11 5 Ministry of Economic Development <http://www.med.govt.nz/buslt/ intprop/info-sheets/wai-
262 .html> (last accessed 25 June 2003). 
11 6 Commission on Human Rights Maataatua Declaration on Cultural and lnte//ectual Property 
Rights of Indigenous Peoples (EiC .4/Sub.2/AC.4/1 993/CRP .5, 1993) Recommendation 2.8. 
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developed appropriate protection mechanisms."
117 This declaration was 
subsequently tabled in the United Nations (Working Group on Indigenous Peoples) 
and ratified by 60 States.
11 8 
The foreshore and seabed claim also has implications on the management of 
biological resources in the foreshore and seabed area including the access to 
biological resources and benefit sharing arrangements. The government is currently 
consulting on how to resolve the foreshores and seabed issue with submissions 
closing 3 October 2003. 
The unresolved Wai 262 claim and potentially the outcome of the foreshore 
and seabed claim do create uncertainty around the ownership and possession of New 
Zealand's biological resources. This hinders the ability of the New Zealand 
government to determine rights and obligations in relation to bioprospecting. 
119 In 
fact there is already anecdotal evidence of foreign researchers withdrawing from 
investment in New Zealand because of the perceived uncertainty and risk created by 
Wai 262. 120 Some overseas researchers have expressed their opinion that it is 
impossible to engage bioprospecting in New Zealand, given the issues surrounding 
the Maori claims and intellectual property rights.
121 
2 Traditional knowledge 
A major concern for Maori and other indigenous peoples is that their cultural 
knowledge of plants, animals and the environment are being used for commercial 
gain, often without their informed consent and without any benefits flowing back to 
them. 122 The concern is prompted by a lack of recognition and protection in New 
Zealand's common and statutory law in regards to the use and ownership of 
11 7 Commission on Human Rights Maataatua Declaration on Cultural and /nteffectual Property 
Rights of Indigenous Peoples (EiC .4/Sub.2/AC.4/ 1993/CRP .5, 1993) Recommendation 2.8. 
11 8 Te Puna Kokiri Mana Tangata <http: //www.tpk.govt.nz/publications/docs/tangata/index.htm> 
(last accessed 7 August 2003). 
11 9 Ministry of Economic Development <http://www.med.govt.nz/buslt/intprop/info-sheets/wai-
262 .html> (last accessed 25 June 2003) . 
120 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 3. 
121 Stephen Whitton Bioprospecting in New Zealand (submission to Ministry of Economic 
Development, 2003) . 
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traditional knowledge. This is issue is not unique to New Zealand and other 
countries are considering these matters. It is also considered in a number of foras. 
These locations where populated also possess a wealth of indigenous 
knowledge which is used in a large proportion of the dmgs and pharmaceutical 
products in use today. "Chemical compounds derived from plants, animals and 
micro-organisms are more easily identified and of greatest commercial value when 
collected with indigenous knowledge and or found in territories traditionally 
inhabited by indigenous peoples." 123 According to one international study, which 
surveyed 119 commercially useful plant-based drugs, 74 per cent of these were 
previously known and used in traditional medicine. Medicines derived from plants 
originally used by indigenous peoples have an annual world market of US$43 
billion. 124 
Intellectual property laws require individual or joint authorship to be clearly 
established before protection can be given. Traditional knowledge and traditional 
knowledge-based innovations and practices are developed incrementally over 
several generations and it may be collectively owned. 125 Maori do not view their 
knowledge in terms of property at all as that is something that has an owner and is 
used for the purpose of extracting economic benefits instead they view knowledge in 
terms of community and individual responsibilities. 126 
Other difficulties with usmg intellectual property to protect traditional 
knowledge are that for the most part it is available in the public domain so it is 
unable to be protected by patents or copyright. Patents can only be used for new, 
inventive and useful things. Therefore, anyone can access this information and use it 
for monetary gains without the permission of traditional knowledge holders and 
122 See UNDP, Conserving indigenous Knowledge: Integrating Two Systems of innovation (1994) 3. 
123 J R Axt, M L Com, M Lee, D M Ackerman, Biotechnology, indigenous Peoples and Jntellect11al 
Property Rights (Congressional Research Service, Washington DC: The Library of Congress, 1993) 
6. 
124 NR Farnsworth "Screening Plants for New Medicines" in E O Wilson (ed) Biodiversity ( ational 
Academic Press, Washington DC, USA, 1996) 83, 97 . 
125 The Ministry of Economic Development < http: //www.med.govt.nz/ers/nat-
res/bioprospecting/bioprospecting-qa.html> (last accessed 25 June 2003). 
31 
without needing to share the benefits gained from use of this knowledge.
127 Even if 
intellectual property laws protected it, eventually it would make it into the public 
arena due to limitation on the protection that is currently available.
128 Intellectual 
property is only used or connected to ideas or processes, which have a monetary 
value or where they are used in a commercial application. Traditional knowledge 
does not really fit in that way; it is mostly used to identify a potential resource, 
which could eventually be used to develop a product, which contains those 
characteristics. Therefore, currently anyone can access this information and use it for 
monetary gains without the permission of traditional knowledge holders and without 
needing to share the benefits gained from use of this knowledge.
129 
It is evident that the conventional intellectual property rights systems were 
not designed to anticipate or address the various concerns raised by the CBD in 
relation to matters such as access to genetic resources, equitable benefit sharing, and 
the protection of the traditional biodiversity related knowledge of indigenous 
communities. This has been recognised in international forums such as the World 
Intellectual Property Organisation and the CBD. The protection of traditional 
knowledge is part of the current review of the Patent legislation being undertaken by 
the Ministry of Economic Development. 
130 Where it is not possible to develop 
positive solutions to these concerns within existing frameworks, the government 
sees merit in examining new and alternative models of protection. 
V BENEFIT SHARING 
Benefit sharing has been defined as "all forms of compensation for the 
utilisation of genetic resources, whether monetary or non-monetary, and includes, in 
particular, the participation in scientific research and development on genetic 
126 Te Runanga o Turanganui a Kiwa The Treaty of Waitangi and Bioprospecting (submission to 
Ministry of Economic Development, 2003). 
127 The Major Concerns for Indigenous People < http: //www.icip.lawnet.com.au/ch3.htm> (last 
accessed 28 July 2003) . 
128 Alexander Gillespie Maori, Biodiversity and international law 
http ://lianz.waikato.ac .nz/P APERS/al_gillespie/biodiversity.pdf (last accessed 7 August 2003). 
129 The Major Concerns for Indigenous People < http: //www.icip.lawnet.com.au/ch3.htm> (last 
accessed 28 July 2003). 
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resources, and the making available of the findings of such scientific research and 
development and the transfer of technology."131 The obligations associated with 
benefit sharing do not apply retrospectively to any genetic resources acquired before 
the enactment of the CBD. 132 
The CBD sets out that there is to be an "equitable sharing of benefits" to all 
those who hold a direct stake in the biological resources .133 The difficulties 
associated with benefit sharing are determining what the benefit is and how the 
benefits can be shared in a fair and equitable way. There are also difficulties in 
determining the particular stakeholders as they can include a number of different 
parties, for example government, research institutions, and indigenous people. 134 
There is a real risk if all the stakeholders are not identified at the outset there may be 
repercussions later on, it is also against the principle of equitable sharing under the 
CBD.1 3s 
A A Contractual Approach 
Benefit sharing examples have to date focused on bilateral and contractual 
agreements. 136 The advantages of using contracts are that they are flexible, require 
minimal government involvement, and cost effective. 137 Contracts can ensure that 
direct stakeholders interests can be taken into account and so far they have been used 
130 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 3. 
13 1 Convention on Biological Diversity Building A New Partnership: Draft Guidelines on Access and 
Benefit-Sharing Regarding the Utilisation of Genetic Resources (Submission by Switzerland 
UNEP/CBD/WG-ABS/1 /INF/5, 2001). 
132 Kiichiro Hayashi The International Environment fo r Access to Genetic Resources especially fo r 
moneta,y benefit-sharing matter: Convention on Biological Diversity (Mitsubishi Research Institute 
INC and Ministry of Agriculture, Forestry and Fisheries of Japan, 2000) 10. 
133 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, arts 15(7), 16(1) and 19. 
134 Bioprospecting/Biopiracy and Indigenous Peoples <www. latinsynergy.org/bioprospecting.htm> 
(last accessed 6 July 2003). 
135 Environmental Policies Studies Workshop Access to Genetic Resources: an Evaluation of the 
Development and Implementation of the Recent Regulation and Access Agreements (School of 
International and Public Affairs, Columbia University, 1999) 31. 136 WIPO Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional 
Knowledge and Folklore Operational Principles f or Intellectual Property Clauses of Contractual 
Agreements Concerning Access to Genetic Resources and Benefit Sharing (Second Session, 
WIPO/GRTKF/IC/2/3, 2001). 
137 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002). 
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to ensure benefit sharing in Costa Rica, Brazil, Columbia, Cameroon, the
 
Philippines, Fiji and the United States.
138 
Bioprospecting agreements include both features that are common to 
ordinary contracts and intellectual property licensing agreements as well as features
 
that are specific to the bioprospecting context. Some of the terms in a contract may
 
relate to environmental impacts, cultural sensitivity, sunset and liability clauses
, 
resource control, control of derivative information and resources, immediate benefi
t 
sharing and long term benefit sharing.
139 
B Types of Benefit Sharing Mechanisms 
There are different types of benefit sharing mechanisms, which operate around a
 
contractual framework. 
1 Permits and licences 
Permits can be issued which convey the right to access biological materials. 
The permit can set out conditions of access, for example limiting the type and
 
an1ount of material to be collected, the collection area, the time allowed for
 
collection, acceptable methods for collection and who will do the collecting.
140 
Permits are currently used in New Zealand for obtaining access to resources, rather
 
than benefit sharing. Licences are usually used to gain access and they can grant a
 
property right without transferring the ownership of it.
141 
2 Material transfer agreement 
The purpose of a Material Transfer Agreement (MTA) 1s to transfer 
proprietary material or information to third parties. These are the most common
 
138 Alexander Gillespie Maori, Biodiversity and International Law 
http ://lianz.waikato.ac .nz/P APERS/al_gillespie/biodiversity.pdf (last accessed 7 Aug
ust 2003). 
139 Sarah A Laird "Contracts for Biodiversity Prospecting" in Walter V Reid et al (eds Bi
odiversity 
Prospecting; Using Genetic Resources for Sustainable Development (World Resourc
es Institute, 
Washington DC, 1993). 
140 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Pap
er 
(Wellington, 2002) 26-27. 
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contractual agreements used in bioprospecting because they are generally used for 
research purposes. They are a way to maintain control over access to the materials 
by the owner of the source. The MTA document defines the terms and conditions for 
transferring the material. 142 
3 Cooperative research and development agreements (CRADAs) 
One of the most common examples of a contract is a co-operative research 
and development agreement (CRADA), 143 which are agreements that can be used 
between private industry and national agencies when working together on a mutually 
beneficial research and development project. 144 They can incorporate permits, MT As 
and licences in the one agreement. 145 The agreements set out the roles and 
obligations of the parties and general provisions including legal details and 
assignment of rights. The agreements have several advantages in that the private 
sector can take advantage of the governments facilities, they encourage the 
development of relationships between the government and private sector and there is 
flexibility in regard to intellectual property. 146 
An example of a CRADA is the bilateral contract established between INBio 
and Merck Sharp and Dohme, Inc, a pharmaceutical company. At the time this 
agreement was signed on September 20, 1991, it was "hailed as the wave of the 
future" as it was the first bilateral contract of its kind at the time. 147 INBio is a 
national bioprospecting institution in Costa Rica, which operates as a private non-
profit, public interest association. 148 The objective is for INBio "to promote the wise 
141 Ministry of Economic Development, above, 26-27. 
142 Kim Connolly-Stone "Patents, Property Rights and Benefit Sharing Issues in Relation to 
Bioprospecting" (Bioprospecting in Antarctica Workshop, Christchurch, 7-8April 2003). 143 Edmonds Inst v Babbitt, 42 F.Supp.2d I, 4 (D.C.Cir. 1999). 
144 Biodiversity, Biotechnology and Law Training Course West Africa 
<www.aaas.org/international/africa/gbdi/mod2c.html> (last accessed 7 August 2003). 145 Biodiversity, Biotechnology and Law Training Course West Africa 
<www.aaas.org/international/africa/gbdi/mod2c.htrnl> (last accessed 7 August 2003). 
146 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 26. 
147 Edgar J Asebey and Jill D Kempenaar "Biodiversity: Opportunities and Obligations: The 
Intellectual Property Perspective on Biodiversity:Biodiversity Prospecting: Fulfilling the Mandate of 
the Biodiversity Convention" (1995) 28 Yand.J.Transnat ' l L.703,725. 
148 Walter V Reid and others "A New Lease on Life" in Walter V Reid and others eds Biodiversity 
Prospecting (World Resource Institute, ew York, 1993) 1, 9. 
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management and use of biotic wealth through the development and distribution of 
information on species, genes and ecosystems"
149 lNBio is "fully empowered by the 
Costa Rican government to enter into contracts and agreements with national and 
international institutions and individuals."
150 
Under the agreement between lNBio and Merck, INBio provided 10,000 
extracts from wild plants, insects and microorganisms to Merck who would have the 
exclusive right to analyse the samples for two years. In consideration, INBio 
received an upfront fee of $1 million, $130,000 worth of scientific equipment and a 
royalty from any commercial drug developed from the agreement (thought to be 
between 1 and 3 per cent of net sales, although these provisions are kept secret).
151 
The fact that the royalty provisions have been kept secret is one of the major 
concerns as it is unclear whether Costa Rica is being fairly compensated. 
152 It is 
known that ten percent of INBio's initial revenue and fifty percent of the royalties 
will be paid to Costa Rica's National Park Fund. 
153 This is required under INBio's 
mandate that a percentage of its returns go towards conservation and to employ local 
indigenous communities in collection related jobs.
154 
The lNBio-Merck contract has been successful due to it ensunng the 
sustainability of Costa Rica's biodiversity and still maintaining simple and flexible 
procedures for applying access. The Costa Rica model illustrates that a private 
contract is one way to establish a legal framework within which bioprospecting can 
be conducted. This model has allowed Costa Rica to attract positive investment that 
149 Walter V Reid , abcve, 9. 
15° Christopher J Hunter "Sustainable Bioprospecting: Using Private Contracts and International 
Legal Principles and Policies to Conserve Raw Medicinal Materials" (1997) 25 B.C. Envtl.Aff.L.Rev. 
129, 144. 
151 David R Downes " New Diplomacy for the Biodiversity Trade : Biodiversity, Biotechnology and 
Intellectual Property in the Convention on Biological Diversity" ( 1993) 4 Touro J Transnat 'L L. I , 8. 
152 Edgar J Asebey and Jill D Kempenaar "Biodiversity: Opportunities and Obligations: The 
Intellectual Property Perspective on Biodiversity: Biodiversity Prospecting: Fulfilling the Mandate of 
the Biodiversity Convention" (1995) 28 Yand.J.Transnat'l L.703 , 726. 
153 Walter V Reid "The Economic Realities of Biodiversity" (1993-94) Issues Sci & Tech, Winter, 48, 
50. 
154 Edgar J Asebey and Jill D Kempenaar, above, 725 . 
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has contributed not only to the conservation of the resource but also to the 
infrastructure of the country. 155 
C The Contractual Approach and Indigenous Peoples 
The use of contracts can address issues with traditional knowledge and also 
enable indigenous communities to gain a stake in the benefits. 156 The World Trade 
Organisation Committee on Trade and Environment has recommended contracts as a 
way of effectively providing compensation for traditional knowledge. 157 FORST 
reported that contracts were the most suitable methods for benefit sharing and 
controlling spiritually significant resources. 158 This is because it avoids the cost and 
difficulties of intellectual property provisions. 159 The WIPO Intergovernmental 
Committee on Intellectual Property and Genetic Resources, Traditional Folklore 
("the IGC") has developed as a pilot project, an on-line database of contractual 
practices and clauses relating to intellectual property, access to genetic resources and 
benefit sharing. 160 
Including traditional knowledge in contracts is one way of acknowledging 
the "owners" and use of that knowledge. It can also be a way of protecting that 
knowledge, which may be one of the benefits that could come out of the benefit 
sharing arrangement, as it is difficult to put a monetary value on that knowledge. 
Peru has implemented a system whereby they issue licences, which give permissions 
to use material and traditional knowledge in particular ways. However, the 
application is limited in order to make it consistent with cultural concerns and 
sustainable use. The licences are monitored and enforced by local groups in 
155 Christopher J Hunter "Sustainable Bioprospecting: Using Private Contracts and International 
Legal Principles and Policies to Conserve Raw Medicinal Materials" ( 1997) 25 B.C. Envtl.Aff.L.Rev. 
129, 144. 
156 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 29. 
157 David V Williams Matauranga Maori and Taonga authorised by direction from the Waitangi 
Tribunal 3 May 1996 (Jan 1997) 39, Quoting WTO committee on T& E 8 ov 1996 para 143. 158 The Foundation for Research, Science & Technology is the principles Crown funding body for 
research in ew Zealand. Peter Morten A Discussion Paper on the Foundation for RS&T's 
Intellectual Property Policy (unpublished 2001) 1, 8. 
159 Sarah Ireland, Bioprospecting and the Rights of Indigenous Peoples (LLM Research Paper, 
Victoria University of Wellington, 1999). 
160 <http://www.wipo.int/globalissues/databases/contracts/index.htrnl> (last accessed 7 August 2003). 
37 
conjunction with state authorities which gives the indigenous people control over the 
process. 161 
There are a number of overseas models, which ensure that indigenous 
peoples rights to biological resources are protected . For example in Fiji, 83 percent 
of the land is communally owned by indigenous Fijians and this has been recognised 
by research institutions through bioprospecting contracts. Under the Philippines 
Presidential Executive Order 247,
162 indigenous cultural communities and 
indigenous peoples are recognised as having property and intellectual rights over 
flora and fauna. Any bioprospecting on ancestral lands and domains of indigenous 
communities can only occur with the prior informed consent of such communities, 
which has to be obtained in accordance with the customary Jaws of the concerned 
community. 163 This is provided for as the Free and Prior Informed Consent in the 
Indigenous Peoples Rights Act of 1997 of the Philippines.
164 
The Andean Pact's Common System on Access to Genetic Resources also 
allows the indigenous communities to participate in the process of admission of 
access requests. However, they do not create any type of rights in the knowledge or 
materials under the communities' control. The Philippines Executive Order provides 
for the granting of compulsory licences in case the knowledge or materials that are 
16-
obtained are patented. ) 
However, there is the other extreme where indigenous and local communities 
are not conferred any participation rights at all for example in the Malaysian states 
of Sarawak166 and Sabah.
167 Costa Rica's agreements, including INBio-Merck also 
16 1 Environmental Policies Studies Workshop Access to Genetic Resources: an Evaluation of the 
Development and Implementation of the Recent Regulation and Access Agreements (School of 
International and Public Affairs, Columbia University, 1999) 31. 
162 Philippines Presidential Executive Order 247 1995 . 
163 Republic of the Philippines Executive Order No.247. Traditional Resource Rights 
<http://users.ox.ac.uk/-wgtrr/> (last accessed 7 August 2003). 
164 Republic Act No. 8371 <http ://www.chanrobles.com/republicactno8371.htm> (last accessed 7 
August 2003). 
165 Carlos M Correa "Beyond TRIPs: Protecting Communities ' Knowledge" in Graham Dutfield 
Chapter I 1: Rights, Resources and Responses < http ://www.ubcic .bc.ca/chapterl l .htm> (last 
accessed 8 September 2003) . 
166 The Sarawak Biodiversity (Access, Collection and Research) Regulations, 1998). 
167 Sabah Biodiversity Bill 2000. 
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did not include indigenous communities or compensated for the use of indigenous 
knowledge. 168 Even having the rights and responsibilities stipulated in legislation, 
for example Philippines, may work quite differently in practice. For example the 
PIC form that has to be signed in the Philippines, only says that indigenous 
communities have been notified of a research proposal, not that they agreed to it. 
A current example of a stakeholder situation in New Zealand is the private 
arrangement between Waikato University and Ngai Tuhoe who are working together 
on a project researching the traditional medicinal flora of Ngai Tuhoe. Under this 
arrangement benefits will be shared if any new drugs or treatments are developed 
and commercialised. The Tuhoe representative body will receive 40 percent and 
another 40 percent will be awarded to the trust board for New Zealand Maori. 
Waikato University will receive the remaining 20 percent. Tuhoe also have 
substantial involvement in any decisions relating to the resources. 169 
This type of contract has advantages for both parties, as the research 
institution establishes a relationship with Maori, which can ensure the ability to 
conduct future research. This agreement shows some interesting New Zealand 
developments in creating stakeholder roles for Maori as Ngai Tuhoe have been able 
to protect the ownership of the knowledge, practical use and development and 
control the process through consultation. 170 However the research agreement is still 
in its early stages and as no benefits have been derived to date, it still has to be 
tested. 
There are difficulties with taking a contractual approach, particularly in New 
Zealand. This is because a contractual approach relies on an ability to assert 
ownership or a property right. This may not always be appropriate for use in New 
168 Christopher J Hunter "Sustainable Bioprospecting: Using Private Contracts and International 
Legal Principles and Policies to Conserve Raw Medicinal Materials" ( 1997) 25 B.C. Envtl.Aff.L.Rev. 
129, 158. 
169 United National Educational, Scientific and Cultural Organisation Innovative Measures Required 
to Protect Indigenous Knowledge <http ://www.unesco.org/bpi/eng/unescopress/2002/02-
56e.shtml>(last accessed 9 March 2003). 
170 United Nations Educational, Scientific and Cultural Organisation Innovative Measures Required to 
Protect Indigenous Knowledge <http:// www.unesco.org/bpi/eng/unescopress/2002/02-56e.shtml> 
(last accessed 9 March 2003). 
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Zealand given the outstanding issues of ownership of biological resources under the 
Wai 262 claim. 171 In the Tuhoe and Waikato example, Tuhoe could assert ownership 
over the resource as the research involved specifically looking at indigenous flora 
and fauna to the Tuhoe people. However, using contracts may incur a situation 
where any individual iwi, which may even play a minor kaitiaki role over a 
particular resource could enter into an agreement independently and effectively 
preclude the exercise of rights, and opportunities of other kaitiaki over the same 
resource or knowledge.
172 There are also difficulties where more than one single 
hapu or iwi may have an interest in a particular resource, for example where a 
certain native plant is found throughout the country.
173 Ensuring that sufficient 
consultation takes place can also seem particularly daunting for a foreign institution 
that is unsure of whom to contact and it can be an expensive exercise, which may be 
too much for the smaller private research institution. 
174 
There are also general concerns internationally about the inequality of 
bargaining power between international companies and indigenous communities and 
to the exact nature of agreements that have been negotiated. It is difficult to assess 
these when they are mostly kept secret and therefore cannot be independently 
assessed. 
VI A BIOPROSPECTING FRAMEWORK IN NEW ZEALAND 
The government has put forward three options for consideration to ensure 
that New Zealand can achieve a more comprehensive position on bioprospecting. 
These do not necessarily need to be mutually exclusive. 
175 The options are is to 
issue a government policy statement, establish a government co-ordinating authority 
17 1 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 28 . 
172 Te Iwi o Te Roroa and the Waipoua Forest Trust (submission to Ministry of Economic 
Development, 2003). 
173 Te Runanga o Ngai Tahu Discussing the Options- Bioprospecting in New Zealand (submission to 
Ministry of Economic Development, 2003). 
174 MED Website <http: //www.med.govt.nz/ers/nat-
res/bioprospecting/submissions/summary/index.htm1> (last accessed 7 July 2003). 
175 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 22 . 
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and to develop benefit sharing to capture benefits at the national level and share 
benefits with Maori. 176 
A Government Policy Statement 
A government policy statement would provide guidance to the vanous 
agencies in how to discharge their functions in relation to bioprospecting. 177 The 
policy statement should advocate the need for access and benefit sharing regimes 
that will facilitate bioprospecting activity. It could provide an overarching 
framework for bioprospecting activities, clarifying a number of policy objectives. 
This is important, particularly for foreign investors and both foreign and New 
Zealand researchers (and other interested parties) the Government's position on 
bioprospecting, i.e., "to take advantage of economic development opportunities and 
other benefits whilst safeguarding environmental, social and cultural values". 178 It 
could also provide a list of guiding principles for Crown-managers of biological 
resources and place the policy in context to other policy, for example Oceans Policy 
and the Wai 262 Claim. The aim of any proposed framework is to establish a 
consistent policy framework, which "precludes duplication, restrictive legislative 
requirements and prohibitive costs from discouraging bioprospecting and thereby 
minimising the benefits that bioprospecting could bring to New Zealand." 179 
The advantage of this approach is that it provides clarity and reqmres 
minimal intervention. However, the difficulty with a policy statement is that it can 
be implemented differently by the various agencies involved. This is the problem 
with the current regime to date due to the various agencies are implementing 
different management regimes. Therefore, there is a requirement for further policy 
development to ensure that any access and benefit sharing regimes will facilitate 
bioprospecting. There are two options either to introduce specific legislation to 
regulate access and benefit sharing regimes for bioprospecting activities or to review 
and improving the existing legislation to facilitate access and benefit sharing. 
176 Ministry of Economic Development, above, 6. 
177 Ministry of Economic Development, above, 22 . 
178 Ministry of Economic Development, above, 21. 
179 Ministry of Economic Development, above, 21. 
41 
B A Legislative Approach 
The introduction of specific legislation to implement the obligations under 
the CBD, is an option taken by some countries, including Australia, Philippines, 
Costa Rica and the Andean Pact. Brazil and Peru have got bills currently under 
deliberation. 180 The Philippines were the first country to legislate in May 1995. The 
Presidential Executive Order No. 247 sets out a very strict regulatory framework, 
which asserts sovereign rights over biological resources.
181 The order lays down 
three essential conditions for bioprospectors in the Philippines. Prospectors have to 
negotiate a commercial or academic research agreement with the Government, 
182 
seek prior informed consent of both the Government and indigenous cultural 
communities 183 and share benefits with local communities and indigenous peoples, 
including ownership of intellectual property and material. The Order also establishes 
an institutional structure to act as the Competent National Authority on these 
matters. 184 
There are two types of research agreements, the Commercial Research 
Agreement (CRA) which you must get if you are a private person, corporation, 
foreign or international entity, and the Academic Research Agreement (ARA) which 
you can be granted if you are a researcher with a governmental or inter-
governmental agency. 
185 If the academic research has commercial potential, or 
should you wish to transfer the collected materials to a third party, your ARA must 
be upgraded to the CRA category.
186 The access permit requires the applicant to 
18° Kiichiro Hayashi The International Environment for Access to Genetic Resources especially for 
moneta1y benefit-sharing matter: Convention on Biological Diversity (Mitsubishi Research Institute 
INC and Ministry of Agriculture, Forestry and Fisheries of Japan, 2000) 19. 
181 Philippines Presidential Executive Order 247 1995 "Prescribing Guidelines and Establishing a 
Regulatory Framework for the Prospecting of Biological and Genetic Resources, their By-Products 
and Derivatives, for Scientific and Commercial Purposes, and for other Purposes." The Philippines: A 
Bridle on Bioprospecting? Grain <http: //grain.org/publications/jun972-en.cfm> (last accessed 7 
August 2003) . 
182 Philippines Presidential Executive Order 247, section 5. 
183 Philippines Presidential Executive Order 247, section 2. 
184 Philippines Presidential Executive Order 247, sections 6 and 7. 
185 The Philippines: A Bridle on Bioprospecting? Grain <http://grain.org/publications/jun972-en.cfm> 
(last accessed 7 August 2003). 
186 The Philippines: A Bridle on Bioprospecting? Grain<http://grain.org/publications/jun972-en.cfm> 
last accessed 7 August 2003). 
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enter into a benefit-sharing contract. It also reqmres the applicant to leave any 
duplicates of samples with local agencies. Since the legislation, the Philippine 
government has approved only 2 out of 37 applications for access to genetic 
resources by commercial and academic interests. 187 
Some developing countries have tackled this issue as a region. This is 
referred to as the Andean Pact; these countries are Bolivia, Columbia, Peru, and 
Venezuela. The participating countries contracted a regional agreement called the 
Carthagena Decision 391 on the issues relating to genetic resources, access and 
benefit sharing. This Decision requires the Andean Pact countries to have domestic 
laws relating to genetic resources . 
Many of the developing countries are the first to implement controls over 
bioprospecting. This is because prior to the CBD, these countries had unregulated 
access to genetic resources, which they are now attempting to rectify with new 
legislation. This differs from the situation in New Zealand where there is existing 
access legislation, albeit that they were not specifically designed to comply with the 
goals of the CBD. New Zealand's situation is similar to Australia as we both have 
access regimes in place, although in an ad hoe fashion and not for the purpose of 
bioprospecting. However, Australia have recently implemented a regulatory 
framework under their Environmental Protection and Biodiversity Conservation Act 
1999 which will provide for an access and benefit sharing contract scheme to 
biological resources in Commonwealth areas .188 This was particularly in response to 
concerns over their ad hoe legislative framework acting as a disincentive to 
bioprospecting. 189 
More recently Australian States have also began exammmg access and 
benefit sharing regimes. The Queensland government have released a draft 
187 Environmental Policies Studies Workshop Access to Genetic Resources: an Evaluation of the 
Development and Implementation of the Recent Regulation and Access Agreements (School of 
International and Public Affairs, Columbia University, 1999) 3 1. 
188 Environment Australia Access to Biological Resources in Commonwealth Areas: Commonwealth 
Public Inqui,y (Australia, 2000) . 
189 Environment Australia Access to Biological Resources in Commonwealth Areas: Commonwealth 
Public Inquiry (Australia, 2000). 
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Biodiscovery Bill 2003. The Bill seeks to facilitate sustainable access, protect native 
biodiversity, encourage value adding, and ensure benefits are shared (by all) through 
benefit sharing agreements.
190 The Queensland's draft Bill, sets out a very 
comprehensive statutory process, although to a lesser extent than in the Philippines. 
Applicants require a "Biodiscovery Collection Authority before they can 
bioprospect." 191 This allows a company site-specific access to native biological 
resources. This access would be monitored by the Environmental Protection Agency 
to ensure enviromnental sustainability. 
The regulatory framework will also implement a "mandatory commercial 
benefit sharing agreement" with the Queensland Government whereby a royalty 
would be paid to the State for any commercial product developed using 
Queensland's resources. 192 Companies will also have to adhere to a Code of Ethical 
Practice for Biotechnology in Queensland. 
193 There are penalties, up to $750,000,
194 
for those who illegally bioprospect, do not enter into a benefit sharing agreement and 
for those who give false or misleading information. 
195 
There are differences between Australia and New Zealand, which suggests 
that New Zealand may not necessarily come to the same conclusion by 
implementing a specific piece of legislation. Australia and its States have researched 
and evaluated the extent of bioprospecting activity being undertaken in their country. 
New Zealand is currently unsure as to the extent of the activity, what is reported is 
suggests it is a relatively small amount. New Zealand does have an issue with the 
Jack of reporting facilities. Australia also asserts ownership over their genetic 
resources. Ownership over biological resources is an unresolved issue in New 
Zealand. There is a risk that if New Zealand were to impose new legislation it could 
be challenged as pre-judicial to the Crown's response to the Wai 262 claim, once the 
190 Draft Queensland Biodiscovery Bill 2003 Explanatory Notes. 
191 Draft Biodiscovery Bill 2003 (Qld), cl 10. 
192 Draft Queensland Biodiscovery Bill 2003 Explanatory Notes. 
193 Queensland Government "Biodiscovery to Deliver Smart State Dividends to Taxpayers" 23 June 
2003 < http://statements.cabinet.qld.gov.au/cgi-bin/display-statementp l 2id- l 3053@db-media> (last 
accessed 8 July 2003). 
194 A fine for a corporation who enter land or water and collect for biodiscovery without a BCA. 
195 Draft Biodiscovery Bill 2003 (Qld) , cl 51 and 52. 
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Tribunal has reported. There are also other factors to take into account such as the 
time involved to introduce specific legislation. 
Australia's legislation at the federal level and Queensland' s draft Bill 
implement a comprehensive process, which makes it difficult to access the 
biological resources. This creates a situation where instead of facilitating 
bioprospecting it discourages interest and investment. Restrictions on bioprospecting 
will mean that bioprospecting activity is more likely to occur illegally or privately 
owned land will be used more than publicly owned land, especially with the 
complicated concessions regime under the Conservation Act. Additional layers of 
regulation associated with the use of public lands for bioprospecting will only have 
the effect of increasing this trend. However, public land can have generally a higher 
degree of biodiversity than domestic land so it is more valuable to bioprospectors. 196 
Currently there are no controls over private land in New Zealand. Other countries 
have used the PIC regime, although it is difficult to enforce. If New Zealand put in 
place a regime over private land then it would probably have to be part of the 
process under the RMA. 
Making any bioprospecting framework too difficult may also affect New 
Zealand's access to other countries biological resources and knowledge gained from 
those resources. New Zealand has to take into account our international obligations, 
which may differ from other countries. For example, Brazil, who is still in the 
process of implementing its legislation, 197 only allows research if it is conducted in 
conjunction with recognised Brazilian researchers. 198 It has been suggested that a 
similar approach be taken as Brazil, where any research undertaken in New Zealand 
is in partner with a New Zealand research agency. 199 Although it may be appropriate 
to require that research be undertaken with or by New Zealand research institutions 
it raises potential market-access and or national treatment issues. While this 
196 Landcare Bioprospecting in New Zealand: Discussing the Options (submission to Ministry of 
Economic Development, 2003). 
197 Senator Osmar Dias' Bill o. 306/95. 
198 Brazil Sees Promise in Jungle Plants, but Tribes See Peril 
<http ://forests.org/archive/brazil/brseesp2.htm> (last accessed 9 September 2003). 
199 Ministry of Economic Development: Overview of Major Issues raised by Stakeholder groups. 
http://www.med.govt.nz/ers/nat-res/bioprospecting/submissions/summary/summary-02.html (last 
accessed 4 August 2003). 
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requirement would not conflict with the General Agreement on Trade in Services, it 
would raise potential issues for the Protocol on Trade in Services to the Australia 
New Zealand Closer Economic Relations Trade Agreement (the Services Protocol). 
Under the Services Protocol, New Zealand must allow Australians and 
Australian Service Providers market access rights no less favourable than those 
allowed to New Zealanders and New Zealand Service Providers. Although New 
Zealand has exempted two service areas from the provisions of the Services 
Protocol, neither exemption includes research services. If New Zealand were to 
require bioprospectors to prefer New Zealand research institutions, Australian 
research institutions would not be getting the same market access as their New 
Zealand counterparts. This amounts to a breach of the Services Protocol. Therefore 
implementing a system that gave preferential treatment could be considered 
inappropriate. 
C Review Existing Regimes 
In order to achieve clarity, and taking into account the shortcomings of a 
specific legislative approach for New Zealand at this stage, the preferred approach 
may be review the existing legislation and develop a set of proposals, which will 
simplify access to biological resources. 
200 This approach could address the problems 
with the existing access regimes, which are too complicated. Simplified procedures 
would avoid any unnecessary compliance and administrative costs that a new regime 
would create. 
A review would ensure that respective agencies collect statistics on the 
extent of bioprospecting activities being undertaken. It may prove that more is 
happening then currently evident which may suggest new legislation is required. At 
the moment the division of responsibility for granting access to different 
environments is appropriate. Different considerations apply when granting access to 
land or the marine environment. 
200 Landcare Bioprospecting in New Zealand: Discussing the Options (submission to Ministry of 
Economic Development, 2003). 
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This approach can also compliment a government policy statement. Both 
these approaches would ensure that the government recognises other policy 
processes and the Wai 262 claim but does not prejudice them. 
However the Conservation Act access regime does have the following 
advantages in that it provides a framework for environmental impacts, the 
opportunity for benefit sharing (condition of consent) and a monitoring framework 
to collect statistical information about bioprospecting activity.201 The RMA also has 
the ability to consider contracts for benefit sharing and environmental impacts. The 
RMA has the advantage of wider appeal rights and greater public involvement in the 
consent process as well as the process for preparing plans/policy statements than 
under the Conservation Act. 
There is an argument that any bioprospecting policy should wait until the 
Wai 262 claim is resolved, 202 however it is highly unlikely that this will happen 
anytime soon. In the meantime there is no protection over New Zealand ' s biological 
resources. Implementing a government policy statement and reviewing the 
legislation would ensure that a bioprospecting framework does not assert ownership 
over biological resources, as any specific legislation may prejudice the outcome of 
the claim.203 It would also support the Governments position that any development 
of a bioprospecting framework will not address the issues raised by Wai 262, such as 
the ownership of indigenous flora and fauna, or the suitability of New Zealand ' s 
intellectual property system for the protection of indigenous knowledge. 204 
20 1 Caron Mounsey-Smith Issues fo r Access to Biological Resources on l and fo r the Purposes of 
Bioprospecting (Ministry of Economic Development, Working Draft, 2003). 
202 Submissions to Ministry of Economic Development, 2003. 
203 Ministry of Economic Development < http://www.med.govt. nzJers/nat-
res/bioprospecting/bioprospecting-qa.html> (last accessed 25 June 2003). 
204 Ministry of Economic Development Bioprospecting in New Zealand: Discussion Paper 
(Wellington, 2002) 29. 
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D Co-ordinating Authority 
A co-ordinating authority could provide a one-stop shop for bioprospecting, 
given the number of agencies involved in managing access to biological resources. 
The authority could act as a clearinghouse for applications and collect 
information.205 It could also provide one contact for both New Zealand and foreign 
researchers or investors. This is similar to the experience in Costa Rica with INBio. 
However, in comparison New Zealand has a much higher level of scientific 
infrastructure and capacity of collaborating institutions to add value to genetic 
resources through technology and knowledge. New Zealand should be able to utilise 
and protect our biodiversity with a greater level of autonomy. Another major 
difference between the two countries is that the areas that INBio collects natural 
products are devoid of indigenous people. Therefore there are none of the 
contentious issues that New Zealand must address in respect to ownership and 
compensation for indigenous knowledge. 
Under the CBD, there is a requirement that Parties obtain prior informed 
consent before undertaking any research activities with another Parties biological 
resources. It would make it easier if New Zealand established an official 'Competent 
Authority,' providing one point of contact to obtain that consent. It could be very 
difficult for overseas governments to find the correct agency, and even then, 
currently there is no agency or Minister that is formally mandated to give such 
permission. 206 This could cause delay, minimising the risk that foreign researchers or 
investors will go elsewhere. 
The presence of such an authority is essential to effectively regulate access to 
biological resources. Effectively controlling access to resources will be the best way 
to marshal any benefits that can accrue to New Zealand from foreign research. 
However, there is a question as to whether there is a genuine need for a 
205 Ministry of Economic Development, above, 23. 
206 Ministry of Economic Development, above, 29. 
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bioprospecting co-ordinating authority in a country as small as New Zealand, given 
that it is not currently known how much bioprospecting activity is being undertaken. 
In the Costa Rican model, INBio was set up because of the large amounts of 
bioprospecting and the fact that Costa Rica is one of the richest biological regions in 
the world, containing nearly four percent of all the world's terrestrial species half a 
million species. 207 New Zealand does not have the same level of interest from 
overseas researchers, at least not in the terrestrial environment. A co-ordinating 
authority may be appropriate if a review reveals a substantial amount of 
bioprospecting activity. 
E Voluntary or Mandatory Frameworks for Benefit Sharing 
A benefit-sharing framework could impose either a voluntary or mandatory 
obligations on bioprospectors. Australia has opted for a voluntary scheme in regards 
to contracts for benefit sharing in commonwealth areas. They have provided a series 
of model contracts.208 However, many countries have made benefit-sharing 
arrangements mandatory as a condition to obtaining access to the resource, including 
Queensland. A mandatory regime would ensure that benefits were being obtained for 
New Zealand rather then a voluntary arrangement. However, once again they can act 
as a disincentive. Any benefit sharing arrangement would need to ensure flexibility 
so that different types of benefits could be determined on the particular project. A 
voluntary contract system with clear benefits as an incentive to participation and 
with an authority to help parties develop the contract. 
There are difficulties involved with how benefits and what benefits are 
shared. There needs to be a separation between direct sharing that relates to genetic 
resources access and development activities and indirect sharing that indirectly 
relates to an individual project. 
207 Ana Sittenfeld and Renata Yillers "Exploring and Preserving Biodiversity in the Tropics: The 
Costa Rican Case" ( 1993) 4 Curr. Opinion in Biotechnology 280, 281 . 
208 Environment Australia Access to Biological Resources in Commonwealth Areas: Commonwealth 
Public Inquiry (Australia, 2000). 
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F Information 
Any bioprospecting policy should ensure that information is available for 
both New Zealand and foreign researchers, which could help facilitate 
bioprospecting. There is also a requirement that information is needed on the extent 
of bioprospecting activity in New Zealand to justify any greater degree of 
intervention or changes to the existing regulatory framework. 
It is import to collect and share accurate infom1ation on the use of biological 
resources. A country cannot track the use of its genetic resources, or assess the 
efficacy of benefit sharing measures unless it is clear what, where and how activities 
are taking place. Accurate information also facilitates further research and 
investment and allows monitoring of how genetic resources (and benefits derived 
from their use) are moving between countries. 
A single database would be very valuable both to revisit previous hits in the 
light of new knowledge and avoid duplication of effort. However, the management 
of the intellectual property in bringing this collection together will not be 
straightforward. This is something that could be implemented into the existing 
legislation. A better system can promote increased knowledge of the activities that 
are occurring in relation to our indigenous flora and fauna. To do this efficiently it 
will need to maintain a database of current research and development. However, 
maintaining a database is problematic and would require access to be readily 
available to researchers and environmental protection agencies. The logistics of this 
could be very difficult, especially when dealing with sensitive information. There 
are also obligations under the CBD to catalogue our biodiversity. 
G Maori and Bioprospecting 
In light of resolving the Wai 262 there is a requirement to address Maori 
issues under any bioprospecting regime and implement a framework that ensures 
Maori are consulted with in regard to any bioprospecting activity and that ensures 
that benefits can be shared with Maori from any activity and use of traditional 
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knowledge. 209 An authority or panel could assess the extent to which Maori has 
traditional knowledge in the particular area, either geographic or scientific. There 
may be a need to distinguish knowledge of, for example biotechnological 
applications of a plant from knowledge that the plant exists. This group would 
ensure on going consultation with Maori on these issues which is particularly 
important due to the unresolved status of the Wai 262 claim 
One proposal is to establish a Maori reference group. This group could 
provide guidance during policy development on possible benefit-sharing 
arrangements as well as options for providing greater recognition of the principles of 
the Treaty of Waitangi. This group could look at the possibilities of a Maori register 
or bringing together information that has already been done in this area to one place. 
Ensure prior informed consent is obtained, that the particular iwi or hapu can be 
identified. This group could be drawn from specialists in issues relating to traditional 
knowledge and genetic resources. It would also support the number of submissions, 
which emphasised the importance of consultation and involvement of Maori in the 
decision-making process. 210 
The ability to use traditional knowledge to develop new products has the 
potential to create new businesses in New Zealand. This knowledge can, therefore be 
of commercial value. An initiative that may go some way to addressing the issue 
within New Zealand is the establishment of the Maori Consultative Committee 
under the Patents Act 1953. This committee will advise the Commissioner of Patents 
whether an invention claimed in a patent application is derived from or appears to be 
derived from traditional knowledge, indigenous plants and animals or whether the 
commercial exploitation of such inventions is, or likely to be, contrary to Maori 
values. Further complementary mechanisms will be required, however, to fully 
address Maori concerns in this area. Officials are actively engaged in work 
underway internationally in the CBD and WIPO to identify possible mechanisms to 
provide this degree of protection. 
209 Convention on Biological Diversity (5 June 1992) 31 I.L.M 954, art 8(j). 
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I A registry of indigenous Maori knowledge 
A mechanism govemmg access to genetic resources and benefit sharing 
might include a register, which records knowledge of botanical species, their use and 
prior infonned consent by Maori. This could potentially help in regard to the 
ownership issues over genetic resources. There are such projects being undertaken in 
an ad hoe way by Crown Research Institutes, Universities and Iwis to record and 
compile knowledge of biological resources and their use by Maori. There is such a 
project in India coordinated by the Centre for Ecological Sciences of the Indian 
Institute of Science (IISc) to create People's Biodiversity Registers. 
A central agency will enable potential bioprospectors to identify which iwi or 
hapu could have a particular interest in a biological resource. Maori would have 
better control over the access of these resources and therefore ensure their role in a 
benefit sharing arrangement. It would enable access to information on the products 
that they are currently manufacturing in terms of the potential relevant indigenous 
knowledge. Information on the traditional uses of a product often adds value in the 
market place. 211 
However, it is unlikely that such a centralised system could occur given that 
some Maori do have concerns over the public disclosure of traditional knowledge in 
this way. Knowledge is considered by some to be sacred and therefore may not 
agree to it being quantified or categorised. 212 The sheer logistics of sourcing, 
compiling, verifying and networking the knowledge may not be justified in terms of 
the benefits that Maori may receive from the database. 
2 10 
Interview with Caron Mounsey-Smith, Senior Policy Analyst (the author, Wellington, 8 
September, 2003). 
2 11 David Downes "How Intellectual Property can be a Tool to Protect Traditional Knowledge" 
(2000) Colum. J. Envtl. L 253 , 278 . 
2 12 
Catherine Davis " Te Matauranga Maori I Te Taha O Te Matauranga" 1997 (LLM Research 
Paper, VUW). 
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2 Certificates of origin 
Certificates of origin are one way of protecting traditional knowledge and 
identifying use of genetic resources. These have been proposed by a Peruvian non-
governmental organisation to make patent law more compatible with provisions in 
the CBD. This system could be achieved through implementing an international 
certification system. It would require countries of origin to issue the certificates 
indicating all that all obligations under the CBD had been fulfilled such as PIC, 
equitable benefit sharing and perhaps other conditions imposing limitations on the 
use of genetic material or knowledge. Patent applications would then need to include 
these certificates without which they would automatically be rejected. The system 
would not affect indigenous communities ' right to veto access to and use of their 
knowledge or resources .213 Implementing this system would definitely add to the 
compliance costs and would require the necessary co-ordination of departments. 
3 Trade secrets 
A trade secret is where valuable information is protected by virtue of its 
being known only to the firm using it. This could potentially be one way of 
protecting the intellectual property of indigenous peoples. If the traditional 
knowledge could be defined as a trade secret and then one could use MT As to 
establish the conditions on benefit sharing. 214 
H Limitations of a Bioprospecting Regime 
The implementation of any bioprospecting regime does not necessarily 
resolve all the issues associated with bioprospecting. There are practical limitations 
as to how extensively the government can monitor a bioprospecting regime. 
Relevant agencies cannot inspect everyone visiting their respective management 
areas and check to see if the benefit partners were meeting the conditions of there 
2 13 Graham Dutfield Chapter 11 : Rights, Resources and Responses 
http://www.ubcic.bc.ca/chapterl 1.htm (last accessed 5 September 2003). 
2 14 Graham Dutfield Chapter 11 : Rights, Resources and Responses <http://www.ubcic.bc.ca/Chapter 
11 .htm> (last accessed 15 July 2003). 
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sharing arrangement. There are difficulties, particularly if a foreign partner were 
involved. Is it simpler to allocate access rights, perhaps charge fees and let private 
sector contracts deal with the balance of benefit sharing problems? 
It is also almost impossible to control the illegal transfer of genetic material. 
Micro-organisms can be cultured from much less than a handful of soil, and genes 
and can easily fit into an airmail envelope. It can be difficult to distinguish the 
country of origin from examining an organism, and even more so if it has been 
manipulated in some way. 215 Authorised access permits, as mechanisms to create 
and control regulatory systems are important tools but not enough to guarantee good 
bioprospecting practices. It is never going to be easy to determine where someone 
applying for a patent got their original idea. In this context, other measures such as 
promoting the use of Certificates of Origin from source countries as a requirement 
for patent applications may help to track down sources of biological and genetic 
material. However, no system, legislative or otherwise is necessarily going to 
prevent biopiracy. 
Legislation cannot be retrospective, and therefore there may be issues in 
regard to bioprospecting, which is being undertaken under the current regime. For 
example, when Costa Rica implemented its Biodiversity Law, in 1998216 there were 
already six contracts with transnational companies, which had been signed. 21
7 The 
new legislation introduced a system whereby prior informed consent from 
indigenous authorities was required where bioprospecting takes place on their lands. 
218 This was not required under the previous system and has resulted in a number of 
215 G Tamayo, A Sittenfield, and W ader "Biodiversity for the Bioindustries" in B.V Ford-Lloyd, H 
J ewbury and JA Callow (eds) Biotechnology and Plant Genetic Resource: Conservation and Use 
(CAB International, Oxon, UK, 1996) 38. 
216 Biodiversity Law, The Legislative Assembly of the Republic of Costa Rica (1998). 
217 Vivianne Solis Rivera and Patricia Madrigal Cordero "Costa Rica 's Biodiversity Law: Sharing the 
Process" (1999) J. Int'l Wildlife L. & Pol 'y, Vol 2, No.2 260 <http:// 
www.jiwlp.com/contents/Crarticle.pdt> (last accessed 9 September 2003). 
218 Vivianne Solis Rivera and Patricia Madrigal Cordero "Costa Rica 's Biodiversity Law: Sharing the 
Process" (1999) J. Int ' l Wildlife L. & Pol 'y, Vo! 2, No.2 260 <http :// 
www.jiwlp.com/contents/Crarticle.pdt> (last accessed 9 September 2003). 
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issues with those who already have activities underway seeking to avoid regulation 
under the new Biodiversity Law. 219 
Uncertainty over legislative requirements or dismption can also have a 
negative effect on bioprospecting. An example is a situation where a bioprospecting 
project covering Brazil, Mexico and Venezuela was halted in the year 2000. This 
was because a newly elected government said that Mexico's bioprospecting 
legislation needed reviewing. 220 This frustrated the pharmaceutical companies and 
researchers who turned their attention to other countries.221 An effect of over 
legislating can also make legal bioprospecting too hard and therefore it continues 
without adhering to any benefit sharing arrangements. 
VII CONCLUSION 
Bioprospecting is a controversial area and such agreements have generally 
failed to acknowledge the source of the materials, information and there is the 
frequent absence of equitable benefit sharing agreements. The CBD is attempting to 
address this issue by encouraging parties to set up access and equitable benefit 
sharing arrangements, which must also take into account indigenous communities. 
However, it is up to individual nations to implement their own access and benefit 
sharing arrangements and consider other legislative reforms, for example intellectual 
property to ensure that they meet their obligations under the CBD. 
It 1s evident, in New Zealand's case, that the special nature of genetic 
materials means that existing legislative structures are inappropriate. The access 
regimes are complicated, each has a different approach to managing bioprospecting 
and there is often no central point of contact. There are also no statutory 
219 Vivianne Solis Rivera and Patricia Madrigal Cordero "Costa Rica 's Biodiversity Law: Sharing the 
Process" (1999) J. Int'l Wildlife L. & Pol'y, Vo! 2, o.2 260 <http :// 
www.jiwlp.com/contents/Crarticle.pdf> (last accessed 9 September 2003). 
220 Diego Cevallos "The Curtain Falls" Bioprospecting' Agreements Abandoned, 
<http: //www.tierramerica.net/2000/1015/article.html> (last accessed 9 September 2003) 685 . 
221 Diego Cevallos "The Curtain Falls" Bioprospecting' Agreements Abandoned, 
<http: //www.tierramerica.net/2000/1015/article.html> (last accessed 9 September 2003) 685. 
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requirements for bioprospectors to share information, technology, or other benefits 
with New Zealand. 
There are a number of overseas models that New Zealand could potentially 
adopt, however also has the added complication of the unresolved Wai 262 claim on 
the ownership of flora and fauna, amongst other things. This makes it difficult to 
adopt any overseas bioprospecting models and potentially creates a barrier for 
foreign investment in the bioprospecting industry in New Zealand. The outcomes of 
the Wai 262 claim have important implications for the management and control of 
indigenous biological resources and for the sharing of benefits from their utilisation. 
There is a need to define and allocate ownership interests in biological 
materials, including genetic materials and determine the extent to which these 
interests can be transferred. Determine how ownership and access controls interact; 
define duties and obligations of bioprospectors and clarify how benefits from 
bioprospecting can be allocated to the potential beneficiaries. 
Bioprospecting contains a number of complex issues, particularly in New 
Zealand's case and therefore there is not one solution to resolving the existing 
uncertainty within the current policy framework. There are a number of policy 
options that can be implemented to address these issues. Firstly, the governrnent 
should present a policy statement providing guidance to the various agencies on how 
to discharge their functions in relation to bioprospecting. This would be able to 
clearly signal New Zealand's position on bioprospecting. 
Secondly, a review of existing access regimes should be undertaken which 
includes the development of proposals to simplify access, facilitate benefit sharing 
and improve the collection of statistics, and provide information which can assist 
those who are undertaking bioprospecting activities. Introducing new legislation 
may be required at a later stage if it is proven that enough bioprospecting activity is 
being undertaken or the current proposals are not working effectively to encourage 
further activity. Finally, more information needs to be supplied to those who wish to 
undertake bioprospecting activity in New Zealand. 
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The advantages of these approaches are that they reqmre minimal 
intervention, avoid compliance and administrative costs and will also reduce the 
barriers of the existing regimes. It also recognises but does not prejudice related 
government processes, Oceans Policy and the Government's response to findings of 
the Waitangi Tribunal Wai 262 claim. Information can also be gathered to find out 
whether there is justification for a specific piece of legislation for bioprospecting. 
These options also reflect the intentions of articles 3 and 15 of the CBD as it seeks to 
safeguard environmental, social and cultural values and establish mechanisms to 
facilitate the capture of benefits. 
Any national measures will also need to be consistent with other obligations 
under the CBD, including the preserving the knowledge of and ensuring equitable 
benefit sharing with indigenous and local communities, and with New Zealand's 
obligations under bi-lateral and multilateral trade agreements. In particular a 
bioprospeoting policy must give careful consideration of Maori interests and uphold 
the principles of the Treaty. What is also evident from this research is that 
bioprospecting contains a number of complex and controversial issues. The future 
development of these resources is potentially an important and high profile industry 
creating a wide range of benefits for New Zealand. Therefore New Zealand's 
resources require protection through regulating access. There is also a need to 
develop further internationally agreed principles to guide countries on access and 
benefit sharing arrangements. 
57 
BIBLIOGRAPHY 
Alexander Gillespie Maori, Biodiversity and International Law 
http ://lianz.waikato .ac.nz/P APERS/al_gillespie/biodiversity.pdf (last accessed 7 
August 2003). 
Antarctica New Zealand Bioprospecting in Antarctica: Discussion Paper 
(Wellington, 2002) . 
Biodiversity Law, The Legislative Assembly of the Republic of Costa Rica (1998). 
Biodiversity, Biotechnology, and Law: West Africa 
<http://www.aaas.org/intemational/africa/gbdi/mod2a.htm> (last accessed 7 August 
2003). 
Bioprospecting/Biopiracy and Indigenous Peoples 
<www.latinsynergy.org/bioprospecting.htm> (last accessed 6 July 2003). 
Carlos M Correa "Beyond TRIPs: Protecting Communities' Knowledge" in Graham 
Dutfield Chapter 11: Rights, Resources and Responses < 
http ://www.ubcic.bc.ca/chapterl 1.htm> (last accessed 8 September 2003). 
Christopher J Hunter "Sustainable Bioprospecting: Using Private Contracts and 
International Legal Principles and Policies to Conserve Raw Medicinal Materials" 
(1997) 25 B.C. Envtl.Aff.L.Rev. 
Columbia University School of International and Public Affairs, "Access to Genetic 
Resources : An Evaluation of the Development and Implementation of Recent 
regulation and Access Agreements" (Environmental Policy Studies, Working Paper 
No 4, New York, 1999). 
58 
iper 
1). 
nca 
gust 
ples 
nam 
< 
and 
als" 
1etic 
~ent 
:tper 
Commission on Human Rights Maataatua Declaration on Cultural and Intellectual 
Property Rights of Indigenous Peoples (E/CN.4/Sub.2/ AC.4/1993/CRP .5, 1993). 
Convention on Biological Diversity Building A New Partnership: Draft Guidelines 
on Access and Benefit Sharing Regarding the Utilisation of Genetic Resources 
(Switzerland Submission, UNEP/CBD/WG-ABS/l/INF/5). 
Convention on Biological Diversity (5 June 1992) 31 I.L.M 954. 
Daniel Brown Bioprospecting: Problem Definition (Ministry of Economic 
Development Research Paper, 2001). 
David R Downes" New Diplomacy for the Biodiversity Trade: Biodiversity, 
Biotechnology and Intellectual Property in the Convention on Biological Diversity" 
(1993) 4 Touro J Transnat'L L. 
Department for Environment and Heritage Access to Biological Resources in South 
Australia: Discussion Paper (South Australia, 2000). 
Draft Queensland Biodiscovery Bill 2003 
General Introduction 1.1 Plant-Derived Drugs Natural products 
http://wwwscholar.lib.vt.edu/theses/available/etd-72198-18137 / 
unrestricted/Body.pd[ (last accessed 7 August 2003). 
Edgar J Asebey and Jill D Kempenaar "Biodiversity: Opportunities and Obligations: 
The Intellectual Property Perspective on Biodiversity:Biodiversity Prospecting: 
Fulfilling the Mandate of the Biodiversity Convention" (1995) 28 Vand.J.Transnat'l 
L. 
Environment Australia Access to Biological Resources in Commonwealth Areas: 
Commonwealth Public Inquiry (Australia, 2000). 
59 
G Tamayo, A Sittenfield, and W Nader "Biodiversity for the Bioindustries" in B.V 
Ford-Lloyd, H J Newbury and J A Callow (eds) Biotechnology and Plant Genetic 
Resource: Conservation and Use (CAB International, Oxon, UK, 1996). 
Interview with Caron Mounsey-Smith, Senior Policy Analyst (the author, 
Wellington, 8 September, 2003). 
J R Axt, ML Com, M Lee, D M Ackerman, Biotechnology, Indigenous Peoples and 
Intellectual Property Rights (Congressional Research Service, Washington DC: The 
Library of Congress, 1993). 
Jane Gunn Bioprospecting in the Marine Environment (Ministry of Economic 
Development Research Paper, 2003). 
John R Adair "The Bioprospecting Question: Should the United States Charge 
Biotechnology Companies for the Commercial Use of Public Wild Genetic 
Resources?" (1997) 24 Ecology L.Q. 
Kim Connolly-Stone Patents, Property Rights and Benefit Sharing Issues in 
Relation to Bioprospecting Bioprospecting in Antarctica Workshop 7-8 April 2003. 
Kiichiro Hayashi The International Environment for Access to Genetic Resources 
especially for monetary benefit-sharing matter: Convention on Biological Diversity 
(Mitsubishi Research Institute INC and Ministry of Agriculture, Forestry and 
Fisheries of Japan, 2000). 
Kristy Hall Bioprospecting Position Paper: What is Bioprospecting and What are 
our International Commitments? (Ministry of Economic Development, 2003). 
M Roberts, W Norman, N Mininnick, D Wihongi and C Kirwood Kaitiakitanga: 
Maori Perspectives on Conservation, Pacific Conservation Biology (Surrey Beatty 
and Sons, Sydney, Australia, 1995) 
60 
'in B.V 
Genetic 
author, 
Jles and 
)C: The 
onom1c 
2003. 
rces 
1ersity 
~at are 
itanga: 
Beatty 
Ministry of Economic Development Bioprospecting in New Zealand: Discussion 
Paper (Wellington, 2002) 
Ministry of Economic Development: Overview of Major Issues raised by 
Stakeholder groups. http://www.med.govt.nz/ers/nat-
res/bioprospecting/submissions/summary/summary-02.html (last accessed 4 August 
2003). 
Ministry of Economic Development< http ://www.med.govt.nz/ers/nat-
res/bioprospecting/bioprospecting-qa.html> (last accessed 25 June 2003). 
Ministry of Fisheries Bioprospecting New Zealand (submission to Ministry of 
Economic Development, 2003). 
Ministry of Foreign Affairs and Trade The WTO Agreement on Trade Related 
Aspects of Intellectual Property Rights (TRIPS) (Information Paper, 1999). 
NR Farnsworth "Screening Plants for New Medicines" in E O Wilson (ed) 
Biodiversity (National Academic Press, Washington DC, USA, 1996) 83, 97. 
Oceans Policy http://www.oceans.govt.nz/policy/index.html (last accessed 25 June 
2003). 
Philippines Presidential Executive Order 247 1995. 
Queensland Government "Biodiscovery to Deliver Smart State Dividends to 
Taxpayers" 23 June 2003 < http ://statements.cabinet.qld.gov.au/cgi-bin/display-
statementp 12id-l3053@db-media> (last accessed 8 July 2003). 
Rebecca Macky Bioprospecting in New Zealand: Access to Resources- on land, in 
water bodies and in the coastal marine area (Ministry of Economic Development, 
2003). 
61 
Republic of the Philippines Executive Order No.247. Traditional Resource Rights 
<http: //users.ox.ac.uk/-wgtrr/> (last accessed 7 August 2003). 
Republic Act No. 8371 <http://www.chanrobles.com/republicactno8371.htm> (last 
accessed 7 August 2003). 
Roger A Sedjo "Property Rights, Genetic Resources, and Biotechnological Change" 
(1992) 35 J.L & Econ. 
S Laird and ten K Kate Biodiversity Prospecting: The Commercial Use of Genetic 
Resources and Best Practice in Benefit-Sharing (Earthscan Publications Limited, 
London, UK, 2002). 
Sarah A Laird "Contracts for Biodiversity Prospecting" in Walter V Reid et al (eds 
Biodiversity Prospecting,· Using Genetic Resources for Sustainable Development 
(World Resources Institute, Washington DC, 1993). 
Sarma Lakshmi "Biopiracy: Twentieth Century Imperialism m the Form of 
International Agreements" (1999) 13 Temp.Int'l & Comp.L.J. 
Stephen Whitton Bioprospecting m New Zealand (submission to Ministry of 
Economic Development, 2003). 
Te Puna Kokiri Mana Tangata 
<http: //www.tpk.govt.nz/publications/docs/tangata/index.htm> (last accessed 7 
August 2003). 
Te lwi o Te Roroa and the Waipoua Forest Trust (submission to Ministry of 
Economic Development, 2003). 
Te Runanga o Ngai Tahu Discussing the Options- Bioprospecting in New Zealand 
(submission to Ministry of Economic Development, 2003). 
62 
:shts 
last 
. ge" 
etic 
~ed, 
:eds 
ient 
of 
· of 
rata 
7 
,and 
The Department of Conservation Draft General Policy Conservation Act and 
Related Legislation August 2003. 
The Major Concerns for Indigenous People < 
http://www.icip.lawnet.com.au/ch3.htm> (last accessed 28 July 2003) . 
The New Zealand Biodiversity Strategy, February 2000 
http: //www.doc.govt.nz/Conservation/The-New-Zealand-Biodiversity-
Strategy/index.asp (last accessed 7 July 2003). 
The Magic Pudding Company Pty Ltd Biotechnology Collaboration between New 
Zealand and Queensland: Opportunities for Growth (Report prepared for Industry 
New Zealand, 2003). 
The Philippines: A Bridle on Bioprospecting? 
Grain<http://grain.org/publications/jun972-en.cfm> last accessed 7 August 2003). 
United Nations Educational, Scientific and Cultural Organisation Innovative 
Measures Required to Protect Indigenous Knowledge <http:// 
www.unesco.org/bpi/eng/unescopress/2002/02-56e.shtml> (last accessed 9 March 
2003). 
Vivianne Solis Rivera and Patricia Madrigal Cordero "Costa Rica's Biodiversity 
Law: Sharing the Process" (1999) J. Int'l Wildlife L. & Pol'y, Vol 2, No.2 260 
<http:// www.jiwlp.com/contents/Crarticle.pdf> (last accessed 9 September 2003). 
Walter V Reid and others "A New Lease on Life" in Walter V Reid and others eds 
Biodiversity Prospecting (World Resource Institute, New York, 1993). 
Walter V Reid "The Economic Realities of Biodiversity" (1993-94) Issues Sci & 
Tech, Winter. 
63 
WIPO Intergovernmental Committee on Intellectual Property and Genetic 
Resources, Traditional Knowledge and Folklore Operational Principles for 
Intellectual Property Clauses of Contractual Agreements Concerning Access to 
Genetic Resources and Benefit Sharing (Second Session, WIPO/GRTKF/IC/2/3, 
2001). 
WTO Ministerial Declaration, September 1986; TRIPs, Preamble. 
LAW LIBRARY 
A Fine According to Library 
Regulations is charged on 
Overdue Books. 
VICTORIA 
UNIVERSITY 
OF 
WELLINGTON 
LIBRARY 
111 1 li1l!1 l1i1l1l1l1i1i l1!!1l1l1i1i1t1t1lii i1l1i11!1liiiii 
3 7 2 12 00719692 4 
64 
1 
1etic 
for 
s to 
12/3 
' 
AS741 
vuw 
A66 
F793 
2003 

